WO2008054192A1 - Use of nutritional compositions for preventing disorders - Google Patents

Use of nutritional compositions for preventing disorders Download PDF

Info

Publication number
WO2008054192A1
WO2008054192A1 PCT/NL2006/050274 NL2006050274W WO2008054192A1 WO 2008054192 A1 WO2008054192 A1 WO 2008054192A1 NL 2006050274 W NL2006050274 W NL 2006050274W WO 2008054192 A1 WO2008054192 A1 WO 2008054192A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
protein
months
visceral
total
Prior art date
Application number
PCT/NL2006/050274
Other languages
French (fr)
Inventor
Renate Maria Louise Zwijsen
Hubertus Josephus Maria Van De Heijning
Eline Marleen Van Der Beek
Katrien Maria Jozefa Van Laere
G??Nther Boehm
Original Assignee
N.V. Nutricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38222322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008054192(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by N.V. Nutricia filed Critical N.V. Nutricia
Priority to PCT/NL2006/050274 priority Critical patent/WO2008054192A1/en
Priority to RU2008130370/13A priority patent/RU2417712C2/en
Priority to HUE06824326A priority patent/HUE026440T2/en
Priority to US12/158,857 priority patent/US20110136732A1/en
Priority to BRPI0620465-1A priority patent/BRPI0620465A2/en
Priority to MYPI20082246A priority patent/MY149164A/en
Priority to CA002634693A priority patent/CA2634693A1/en
Priority to MYPI20082247A priority patent/MY172306A/en
Priority to CA002634117A priority patent/CA2634117A1/en
Priority to CN2006800533029A priority patent/CN101384184B/en
Priority to NZ569264A priority patent/NZ569264A/en
Priority to CA002634895A priority patent/CA2634895A1/en
Priority to AU2006327997A priority patent/AU2006327997B2/en
Priority to PL06824326T priority patent/PL1962823T3/en
Priority to PCT/NL2006/050331 priority patent/WO2007073194A2/en
Priority to CN2006800513063A priority patent/CN101389227B/en
Priority to CN201310014398.XA priority patent/CN103054048B/en
Priority to BRPI0620466-0A priority patent/BRPI0620466A2/en
Priority to EP06824326.0A priority patent/EP1962823B1/en
Priority to ES06824326.0T priority patent/ES2537080T3/en
Priority to AU2006327996A priority patent/AU2006327996B2/en
Priority to PT68243260T priority patent/PT1962823E/en
Priority to CN200680051657.4A priority patent/CN101360489B/en
Priority to JP2008547136A priority patent/JP2009521214A/en
Priority to EP11150747A priority patent/EP2305049A1/en
Priority to EP06824324.5A priority patent/EP1973424B1/en
Priority to AU2006327995A priority patent/AU2006327995B2/en
Priority to PCT/NL2006/050329 priority patent/WO2007073193A2/en
Priority to EP06824323A priority patent/EP1962617A2/en
Priority to BRPI0620451-1A priority patent/BRPI0620451A2/en
Priority to RU2008130365/13A priority patent/RU2444210C2/en
Priority to US12/158,931 priority patent/US20090186803A1/en
Priority to PCT/NL2006/050328 priority patent/WO2007073192A2/en
Priority to RU2008130367/15A priority patent/RU2414905C2/en
Priority to MYPI20082287A priority patent/MY162091A/en
Priority to ARP060105798A priority patent/AR058751A1/en
Priority to ARP060105800A priority patent/AR058753A1/en
Priority to ARP060105799A priority patent/AR058752A1/en
Priority to US12/513,428 priority patent/US20100068149A1/en
Priority to PCT/NL2007/050162 priority patent/WO2008054200A2/en
Priority to RU2009120708/15A priority patent/RU2446827C2/en
Priority to EP07747386.6A priority patent/EP2077902B1/en
Priority to MYPI20091766A priority patent/MY151018A/en
Priority to ES07747386T priority patent/ES2571856T3/en
Priority to AU2007314721A priority patent/AU2007314721B2/en
Priority to MYPI2012001164A priority patent/MY176679A/en
Priority to EP16150456.8A priority patent/EP3025643B1/en
Priority to CN201610573964.4A priority patent/CN106172792A/en
Priority to EP17203951.3A priority patent/EP3335710A3/en
Priority to CA2667856A priority patent/CA2667856C/en
Priority to PL07747386.6T priority patent/PL2077902T3/en
Priority to CN200780048216.3A priority patent/CN101568361B/en
Priority to ARP070104861A priority patent/AR063773A1/en
Priority to ARP070104862A priority patent/AR063774A1/en
Priority to EP12175365.1A priority patent/EP2510811A3/en
Priority to JP2009535225A priority patent/JP2010509210A/en
Priority to US12/513,472 priority patent/US20100075900A1/en
Priority to AU2007314729A priority patent/AU2007314729B2/en
Priority to CN2007800446186A priority patent/CN101573048B/en
Priority to BRPI0717969-3A priority patent/BRPI0717969A2/en
Priority to EP12175396.6A priority patent/EP2508178A3/en
Priority to EP07834655.8A priority patent/EP2077728B1/en
Priority to NZ576665A priority patent/NZ576665A/en
Priority to RU2009120668/13A priority patent/RU2444912C2/en
Priority to PCT/NL2007/050525 priority patent/WO2008054208A2/en
Priority to CA002667759A priority patent/CA2667759A1/en
Publication of WO2008054192A1 publication Critical patent/WO2008054192A1/en
Priority to US13/357,109 priority patent/US8871218B2/en
Priority to US14/553,166 priority patent/US20150094257A1/en
Priority to US15/057,324 priority patent/US20160175393A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to preventing diseases later in life by administering particular nutritional composition to infants with the age below 3 years.
  • breast-feeding is the preferred method of feeding infants. It has been suggested that breast feeding early in life might influence the occurrence of disorders later in life. However, there are circumstances that make breast-feeding impossible or less desirable. In those cases infant formula and follow-on formula are a good alternative. The composition of modern infant or follow-on formulas is adapted in such a way that it meets many of the special nutritional requirements of the fast growing and developing infant.
  • WO 2005063050 describes a method of increasing lean body mass and reducing fat body mass in infants by administering to an infant, term or preterm, a nutritional formula comprising a source of DHA and ARA.
  • WO 2006057551 relates to an infant nutrition comprising at least one protease inhibitor, a process for preparing such an infant nutrition and use of the infant nutrition for the treatment and/or prevention of childhood obesity and secondary disorders resulting from childhood obesity.
  • WO 03005836 describes dietary products for infant, child and adult nutrition which possess adequate levels and ratios of medium chain fatty acids and omega- polyunsaturated fatty acids.
  • WO 2006069918 describes a method of continuously reducing the circulating level of insulin like growth factor 1 (IGF-I) in the first few months of the life of an infant by administering to the infant a nutritional composition comprising proteins in an amount such that the composition contains less than 2.25g of protein per lOOkcal.
  • IGF-I insulin like growth factor 1
  • the present inventors have recognized certain gaps in the present knowledge on the relation between nutrition in early infancy and the development of diseases later in life.
  • the present inventors have determined that the whole adipose tissue mass of infants is not a good predictor to determine the risks of diseases later in life.
  • Body fat can be distributed and stored in fat tissue at different places within the body. Different fat tissues have different metabolic effects, particularly in infants.
  • Subcutaneous fat in infants has the important function to maintain an adequate body temperature. Fat deposited in the central part of the body (visceral fat) serves only as storage of energy.
  • adipose cells at different locations differ in size and in their protein secretion profile which are potential regulators of glucose and lipid homeostasis.
  • visceral fat mass is a highly metabolically active tissue that releases free fatty acids directly into the hepatic portal vein.
  • visceral adipocyte count is determined in early infancy, and to a lesser extent during puberty. In the other stages of life visceral fat mass is "only" increased through filling of the adipocytes with fat. Cell numbers remain approximately the same throughout adult life. Hence, it is highly desirable to reduce visceral adipocyte proliferation in early infancy without excessively reducing subcutaneous fat mass. Reduced visceral adipocyte count prevents disorders later in life.
  • a main aim of the present invention is to reduce the development of visceral fat mass accumulation in an infant and/or later in life by designing a nutrition to be administered to the infant which ensures maintenance of normal growth and development.
  • the present inventors found a nutritional composition which reduced visceral adiposity and other disorders later in life, particularly diabetes (particularly type 2 diabetes), fasting hyperglycaemia, insulin resistance, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea.
  • the inventors experimentally evidenced that early-in-life administering nutrition wherein the lipid component is relatively low in linoleic acid (LA) and with a low linoleic acid/alpha- lino lenic acid (L A/ AL A) ratio, results in a decreased visceral fat mass accumulation and/or visceral adiposity, particularly results in a decreased visceral fat mass accumulation and/or visceral adiposity later in life.
  • rodents received a specific nutrition (low LA, low LA/ ALA ratio) early- in-life (via the nursing mother), while a control group did not receive the specific nutrition.
  • the animal groups received the same diet high in saturated fat.
  • LC-PUFA long chain polyunsaturated fatty acids
  • DHA docosahexaenoic acid
  • SDA stearidonic acid
  • DPA docosapentaenoic acid
  • EPA eicosapenteenoic acid
  • LC-PUFA are therefore advantageously incorporated in compositions for reducing visceral adiposity and/or disorders later in life.
  • Medium chain fatty acids (MCFA) did not specifically reduce visceral adiposity, but resulted in an overall reduced fat content later in life.
  • MCFA are therefore advantageously included in the present composition, but in a limited amount.
  • the inclusion of MCFA is particularly desirable in the present low LA formula as it prevents LA deficiency.
  • the present invention concerns the use of a composition
  • a composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories, wherein the lipid component comprises (i) linoleic acid (LA) and alpha- lino lenic acid (ALA) in a weight ratio of LA/ ALA between 2 and 6; (ii) less than 14.5 wt.% LA based on total fatty acids; (iii) long chain polyunsaturated fatty acids (LC-PUFA); and optionally (iv) 10-50 wt.% medium chain fatty acids (MCFA) for the manufacture of a nutritional composition to be administered to a non- obese human with the age below 36 months and for preventing the development of a disorder when said human has an age above 36 months, wherein said disorder is selected from the group consisting of type 2 diabetes, fasting hypergly
  • the present invention concerns the use of a composition
  • a composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 60% of the total calories, wherein the lipid component comprises less than 14.5 wt.% linoleic acid based on total fatty acids and a weight ratio of linoleic acid (LA) to alpha- lino lenic acid (ALA) between 2 and 6, for the manufacture of a nutritional composition for a) preventing and/or treating visceral adiposity and/or b) preventing and/or treating the accumulation of visceral fat mass to an excessive amount wherein the nutritional composition is administered to an infant with the age between 0 and 36 months.
  • LA linoleic acid
  • ALA alpha- lino lenic acid
  • the present invention also concerns a composition to be administered to a non-obese human with the age below 36 months, said composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories, wherein the lipid component comprises (i) linoleic acid (LA) and alpha- linolenic acid (ALA) in a weight ratio of LA/ ALA between 2 and 6; (ii) less than 14.5 wt.% LA based on total fatty acids; (iii) long chain polyunsaturated fatty acids (LC- PUFA); and optionally (iv) 10-50 wt.% medium chain fatty acids (MCFA) for preventing the development of a disorder when said human has an age above 36 months, wherein said disorder is selected from the group consisting of type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral
  • the present invention also concerns a composition to be administered to an infant with the age between 0 and 36 months, said composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories, wherein the lipid component comprises less than 14.5 wt.% linoleic acid based on total fatty acids and a weight ratio of linoleic acid (LA) to alpha- lino lenic acid (ALA) between 2 and 6, for a) preventing and/or treating visceral adiposity and/or b) preventing and/or treating the accumulation of visceral fat mass to an excessive amount.
  • Visceral adiposity a lipid, protein and digestible carbohydrate component
  • visceral adiposity refers to a condition with increased visceral fat mass.
  • the term visceral adiposity is also referred to as central obesity.
  • Visceral adiposity is typically caused by (accumulation of) excessive visceral fat mass.
  • Visceral fat also known as organ fat, intra-abdominal fat, peritoneal fat or central fat is normally located inside the peritoneal cavity as opposed to subcutaneous fat which is found underneath the skin and intramuscular fat which is found interspersed in skeletal muscles.
  • Visceral fat includes mesenteric fat, perirenal fat and retroperitoneal fat.
  • Visceral fat stores can suitably be investigated by imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI) and ultrasonography.
  • CT computed tomography
  • MRI magnetic resonance imaging
  • VAT visceral adipose tissue
  • An adult is considered to suffer from visceral adiposity or to have accumulated visceral fat mass to an excessive amount when at the umbilicus level the visceral adipose tissue (VAT) exceeds 100 cm 2 in man, or 90 cm 2 in women (Saito et al, 1009, Int J Obes Suppl 3:S226).
  • Infants generally have about 10% visceral fat mass based on total fat mass.
  • visceral adiposity in infants therefore preferably relates to a situation wherein the visceral fat mass exceeds about 10 wt.% based on total fat (e.g. between 10 and 20 wt.% visceral fat mass based on total fat mass).
  • visceral adiposity is also referred to as 'apple-shaped' obesity, 'android' obesity, 'abdominal' obesity, 'male-type' obesity, 'waist-predominant' obesity, 'truncal' obesity or 'masculine' obesity.
  • a waist circumference above 102 cm in adult man or above 88 cm in adult women indicates visceral adiposity.
  • a waist-hip ratio can be used as indicator for visceral adiposity.
  • Hip-waist ratio's exceeding 0.9 in man and 0.85 in women indicate visceral adiposity.
  • For children of 3-19 years old appropriate cutoffs for age- and sex-dependent waist circumferences can be found in Taylor et al, 2000 Am J Clin Nutr 72:490-495.
  • a subject suffers from visceral adiposity when it meets one or more of the above criteria (regarding VAT, waist circumference or waist-hip ratio treshholds).
  • Accumulation of visceral fat mass to an excessive amount relates to the accumulation of visceral fat mass to a level at which visceral adiposity occurs and can be determined by the same methods as described above for visceral adiposity.
  • Total fat mass can be determined by DEXA (dual-energy X-ray absorptiometry).
  • the present composition is preferably administered to a non-obese human with the age below 36 months, preferably to a non-overweight human with the age below 36 months. Obesity and/or overweight can suitably be determined by a physician.
  • a non-obese infant below 36 months of age has gender specific weight-for -length below the 95 th percentile, more preferably below the 85 th percentile. Gender specific weight-for-length percentiles have been published by Center for Disease Control and Prevention (CDC) in 2000.
  • LA refers to linoleic acid (18:2 n6)
  • ALA refers to alpha- lino lenic acid (18:3 n3)
  • LC-PUFA refers to long chain polyunsaturated fatty acids comprising at least 20 carbon atoms in the fatty acid chain and with 2 or more unsaturated bonds
  • DHA refers to docosahexaenoic acid (22:6, n3)
  • EPA refers to eicosapentaenoic acid (20:5 n3)
  • ARA refers to arachidonic acid (20:4 n6)
  • Medium chain fatty acids (MCFA) are fatty acids and/or acyl chains with a chain length of 6, 8 or 10 carbon atoms.
  • MCFA may also be referred to as medium chain triglycerides (MCT).
  • compositions that have a low LA/ ALA ratio and that are low in LA and that optionally comprise LC-PUFA and optionally comprise MCFA prevent the occurrence of visceral adiposity.
  • a nutritional composition comprising (i) a LA/ ALA ratio between 2 and 6 and (ii) a low LA content ( ⁇ 14.5 wt.% based on total fatty acids) and optionally LC-PUFA (particularly DHA) resulted in a decrease in visceral adiposity later in life and/or a reduced occurrence of disorders later in life.
  • MCFA were found to reduce adiposity in general. This finding further enables the development of an optimal composition, which comprises MCFA, but not in excessive amounts, i.e. between 10 and 50 wt.% based on total weight of fatty acids.
  • the present composition comprises lipid.
  • LA should be present in a sufficient amount in order to promote a healthy growth and development, yet in an amount as low as possible to prevent occurrence of visceral adiposity.
  • the composition therefore comprises less than 14.5 wt.% LA based on total fatty acids, preferably between 5 and 14.5 wt.%, more preferably between 6 and 12 wt.%.
  • Based on total dry weight of the composition the present composition preferably comprises 2 to 5 wt.% LA.
  • the LA content is preferably between 0.3 and 0.55 g LA per 100 ml of the liquid composition.
  • the LA preferably provides between 4 to 8% of total calories in the present composition.
  • the present composition therefore preferably comprises at least 1.6 wt.% ALA based on total fatty acids, preferably between 1.6 and 5 wt.% ALA. Based on total dry weight of the composition the present composition preferably comprises at least 0.30 wt.% ALA, preferably between 0.3 and 1 wt.% ALA.
  • the ALA content is preferably at least 50 mg ALA per 100 ml of the liquid composition, preferably between 50 and 150 mg ALA per 100 ml.
  • the weight ratio LA/ ALA should be well balanced in order to prevent visceral fat mass deposition (e.g. visceral adiposity) and disorders later in life, while at the same time ensure a normal growth and development.
  • the proper ratio was found by the present inventors.
  • the present composition comprises a weight ratio of LA/ALA between 2 and 6, more preferably between 3 and 6, even more preferably between 4 and 5.5, even more preferably between 4 and 5.
  • the lipid component comprises less than 14.5 wt.% LA based on total fatty acids and a LA/ ALA ratio of 2 to 6.
  • the present composition comprises LC-PUFA.
  • LC-PUFA reduces visceral adiposity later in life.
  • the present composition comprises n-3 LC-PUFA, even more preferably EPA, SDA, DPA and/or DHA. It was found that these LC-PUFA decrease the visceral adiposity.
  • the content of LC-PUFA in the present composition preferably does not exceed 15 wt.% of the total fat content, preferably does not exceed 10 wt.%, even more preferably does not exceed 5 wt.%.
  • the present composition comprises at least 0.1 wt.%, preferably at least 0.25 wt.%, more preferably at least 0.5 wt.%, even more preferably at least 0.75 wt.% LC-PUFA of the total fat content.
  • the EPA content preferably does not exceed 5 wt.% of the total fat, more preferably does not exceed 1 wt.%, but is preferably at least 0.025 wt.%, more preferably at least 0.05 wt.% of the total fat.
  • the DHA content preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.%, but is at least 0.1 wt.% of the total fat.
  • the DPA content preferably does not exceed 1 wt.%, more preferably does not exceed 0.5 wt.% of the total fat, but is preferably at least 0.01 wt.% of the total fat.
  • the SDA content preferably does not exceed 0.5 wt.%, more preferably does not exceed 0.25 wt.% of the total fat, but is at least 0.005 wt.% of the total fat.
  • the present composition comprises relatively low amounts or ARA.
  • the ARA content preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.%, more preferably; does not exceed 0.5 wt.%, even more preferably does not exceed 0.25 wt.%, most preferably does not exceed 0.05 wt.% based on total fatty acids.
  • the LC-PUFA, LA and/or ALA may be provided as free fatty acids, in triglyceride form, in diglyceride form, in monoglyceride form, in phospholipid form, or as a mixture of one of more of the above.
  • the present composition contains LC-PUFA in triglyceride and/or phospholipid form.
  • Medium chain fatty acids are fatty acids and/or acyl chains with a chain length of 6, 8 or 10 carbon atoms.
  • the present low LA and low LA/ ALA composition advantageously comprises 10-50 wt.% MCFA based on total fatty acids.
  • LA is an essential fatty acid, meaning that it cannot be synthesized within the body.
  • the present composition comprises a relatively low LA content, it is important that the LA included in the present composition is not converted to energy (by fat oxidation) and therefore not available for anabolic purposes.
  • MCFA can suitably be added. MCFA are easily mobilized in the bloodstream to provide long-lasting energy, rather than being stored as fat and thereby reduce LA oxidation.
  • the present composition advantageously comprises MCFA.
  • the MCFA reduce the accumulation of fat but were found to have no specific effect on visceral fat mass reduction. Therefore, the present composition preferably comprises 10 to 50 wt.% MCFA based on total fatty acids, more preferably 20 to 40 wt.%.
  • the present composition contains at least one, preferably at least two lipid sources selected from the group consisting of linseed oil (flaxseed oil), rape seed oil (including colza oil, low erucic acid rape seed oil and canola oil), salvia oil, perilla oil, purslane oil, lingonberry oil, sea buckthorn oil, hemp oil, high oleic sunflower oil, high oleic safflower oil, olive oil, marine oils, microbial oils, black currant seed oil, echium oil, butter fat, coconut oil and palm kernel oil.
  • the present composition contains at least one, preferably at least two lipid sources are selected from the group consisting of linseed oil, rapeseed oil, coconut oil, high oleic sunflower oil, butter oil and marine oil.
  • Table 1 gives preferred characteristics of the lipid component of the present composition
  • One effect of the visceral fat mass is believed to be the stimulation of insulin production, with can result over time in a reduced insulin sensitivity and other disorders and other metabolic disorders.
  • High blood insulin levels stimulate glucose uptake in adipose tissue, resulting in an increased adipose tissue mass.
  • the high insulin levels contributes to increased proliferation of visceral adipocytes, at least partly due to the increased glucose uptake.
  • the present composition therefore preferably maintains low insulin levels.
  • the present composition preferably comprises an ingredient which increases and/or maintains insulin sensitivity. It was found that non-digestible oligosaccharides (NDO) that can be fermented (particularly galacto-oligosaccharides) have a blood insulin tempering effect, and consequently contributes to a reduced proliferation of visceral adipocytes. Additionally it was also recognised that infants ingest more calories when bottle fed compared to a situation where breast feeding occurs. In addition to the compositional features of the lipid component as suggested in the present invention, the effectiveness can further be improved by reducing caloric intake. Limiting dosage of the nutritional composition is however not a feasible option for infants. The present inventors have found that advantageously the present composition comprises non- digestible oligosaccharides.
  • the present composition preferably comprises the present lipid component and a non-digestible oligosaccharide which can be fermented.
  • the combination of the present lipid component and the non-digestible oligosaccharides synergistically reduces the visceral adiposity and/or prevents the development of disorders later in life.
  • the non-digestible oligosaccharides have a DP between 2 and 60.
  • the composition preferably prevents the onset of insulin resistance.
  • the non-digestible oligosaccharide is preferably selected from the group consisting of fructo- oligosaccharides (including inulin), galacto-oligosaccharides (including transgalacto- oligosaccharides), gluco-oligosaccharides (including gentio-, nigero- and cyclodextrin-oligosaccharides), arabino-oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides.
  • the present composition comprises fructo-oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably galacto-oligosaccharides, most preferably transgalacto-oligosaccharides.
  • the composition comprises a mixture of transgalacto-oligosaccharides and fructo-oligosaccharides.
  • the present composition comprises galacto-oligosaccharides with a DP of 2-10 and/or fructooligosaccharides with a DP of 2-60.
  • the galacto-oligosaccharide is preferably selected from the group consisting of transgalacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT.
  • the present method comprises the administration of transgalacto-oligosaccharides ([galactose] n -glucose; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, ...., 59 ,60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10).
  • Transgalacto-oligosaccharides are for example sold under the trademark VivinalTM (Borculo Domo Ingredients, Netherlands).
  • the saccharides of the transgalacto-oligosaccharides are ⁇ - linked.
  • Fructo-oligosaccharide is a NDO comprising a chain of ⁇ linked fructose units with a DP or average DP of 2 to 250, more preferably 10 to 100.
  • Fructo- oligosaccharide includes inulin, levan and/or a mixed type of polyfructan. An especially preferred fructo-oligosaccharide is inulin.
  • Fructo-oligosaccharide suitable for use in the compositions is also already commercially available, e.g.
  • Uronic acid oligosaccharides are preferably obtained from pectin degradation.
  • the present composition preferably comprises a pectin degradation product with a DP between 2 and 100.
  • the pectin degradation products is prepared from apple pectin, beet pectin and/or citrus pectin.
  • the composition comprises transgalacto-oligosaccharide, fructo-oligosaccharide and pectin degradation product.
  • the weight ratio transgalacto-oligosaccharide : fructo- oligosaccharide : pectin degradation product is preferably 20-2 : 1 : 1-3, more preferably 12-7 : 1 : 1-2.
  • the present composition preferably comprises in addition to the present lipid component, non-digestible oligosaccharides and/or lactose.
  • the present composition preferably comprises a digestible carbohydrate component, wherein at least 35 wt.%, more preferably at least 50 wt.%, more preferably at least 75 wt.%, even more preferably at least 90 wt.%, most preferably at least 95 wt.% is lactose.
  • the present composition preferably comprises at least 25 grams lactose per 100 gram dry weight of the present composition, preferably at least 40 grams lactose/100 gram.
  • the composition comprises hydrolyzed casein and/or hydrolyzed whey protein. It was found that administration of a composition wherein the protein comprises hydrolyzed casein and hydrolyzed whey results in reduced post-prandial levels of both insulin and glucose compared to the administration of a composition comprising intact casein and intact whey protein. Increased levels of both insulin and glucose indicate a form of insulin resistance in formula fed infants, which is believed contribute to the development of visceral adiposity later- in- life.
  • the present composition preferably comprises at least 25 wt.% peptides with a chain length of 2 to 30 amino acids based on dry weight of protein.
  • the amount of peptides with a chain length between 2 and 30 amino acids can for example be determined as described by de Freitas et al, 1993, J. Agric. Food Chem. 41:1432-1438.
  • the present composition preferably comprises casein hydro lysate and/or whey protein hydro lysate, more preferably casein hydro lysate and whey protein hydro lysate because the amino acid composition of bovine casein is more similar to the amino acid composition found in human milk protein and whey protein is easier to digest and found in greater ratios in human milk.
  • the composition preferably comprises at least 50 wt.%, preferably at least 80 wt.%, most preferably about 100 wt.% of a protein hydrolysate, based on total weight of the protein.
  • the present composition preferably comprises a protein with a degree of hydrolysis of the protein between 5 and 25%, more preferably between 7.5 and 21%, most preferably between 10 and 20%.
  • the degree of hydrolysis is defined as the percentage of peptide bonds which have been broken down by enzymatic hydrolysis, with 100% being the total potential peptide bonds present.
  • the present composition preferably contains 1.5 to 2.25 g protein/100 kcal, preferably between and 1.8 and 2.0 g/100 kcal.
  • Casein Casein is advantageously present since it increases the gastric emptying times by forming a curd in the stomach, thereby increasing satiety.
  • the present composition preferably comprises casein.
  • the composition when the composition is in liquid form, e.g. as a ready-to-drink liquid, the composition preferably comprises at least 0.5 g casein per 100 ml, preferably between 0.5 and 5 gram casein per 100 ml.
  • the composition comprises at least 4 wt.% casein based on dry weight.
  • the casein is intact and/or non- hydro lyzed.
  • Nutritional composition is particularly suitable for providing the daily nutritional requirements to an infant with the age below 36 months, particularly an infant with the age below 24 months, even more preferably an infant with the age below 12 months.
  • the present composition comprises a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories.
  • the present composition comprises a lipid component providing 40 to 50 % of the total calories, the protein component provides 6 to 12% of the total calories and the digestible carbohydrate component provides 40 to 50% of the total calories.
  • the composition preferably comprises 2.1 to 6.5 g fat per 100 ml, more preferably 3.0 to 4.0 g perl 00 ml. Based on dry weight the present composition preferably comprises 12.5 to 40 wt.% fat, more preferably 19 to 30 wt.%.
  • the amount of saturated fatty acids is preferably below 58 wt.% based on total fatty acids, more preferably below 45 wt.%.
  • the concentration of monounsaturated fatty acids preferably ranges from 17 to 60% based on weight of total fatty acids.
  • the present composition is not human breast milk.
  • the present composition preferably comprises (i) vegetable lipid and/or animal (non-human) fat; and/or (ii) vegetable protein and/or animal (non-human) milk protein. Examples of animal milk protein are whey protein from cows milk and protein from goat milk.
  • the present composition does not comprise a proteinase inhibitor, preferably not a trypsin inhibitor, chymotrypsin inhibitor or elastase inhibitor.
  • the present composition preferably comprises at least 50 wt.% protein derived from non-human milk based on total protein, more preferably at least 90 wt.%.
  • the present composition comprises at least 50 wt.% cow milk derived protein based on total protein, more preferably at least 90 wt.%.
  • the present composition comprises acid whey and/or sweet whey with a reduced concentration of glycomacropeptide.
  • the present composition comprises protein derived from ⁇ -casein and/or ⁇ -lactalbumin.
  • the present composition preferably comprises casein and whey proteins in a weight ratio casein:whey of 10:90 to 90:10, more preferably 20:80 to 80:20.
  • the term protein as used in the present invention refers to the sum of proteins, peptides and free amino acids.
  • the present composition is preferably administered in liquid form.
  • the composition preferably comprises 50 to 200 kcal/100 ml liquid, more preferably 60 to 90 kcal/100 ml liquid, even more preferably 60 to 75 kcal/100 ml liquid.
  • This caloric density ensures an optimal ratio between water and calorie consumption.
  • the osmolarity of the present composition is preferably between 150 and 420 mOsmol/1, more preferably 260 to 320 mOsmol/1.
  • the low osmolarity aims to reduce the gastrointestinal stress. Stress can induce adiposite formation.
  • the composition is in a liquid form, with a viscosity below 35 cps as measured in a Brookfield viscometer at 20°C at a shear rate of 100 s "1 .
  • the composition is in a powdered from, which can be reconstituted with water to form a liquid, or in a liquid concentrate form, which should be diluted with water.
  • the preferred volume administered on a daily basis is in the range of about 80 to 2500 ml, more preferably about 450 to 1000 ml per day.
  • Visceral adipocytes proliferate during the first 36 months of life as well as (more limited) in puberty.
  • the present composition is administered to the infant during the first 3 years of life. It was found that there is a predominance of proliferation of visceral adipocytes in the first 12 months of life (optimum in perinatal adipocyte proliferation). Hence, it is particularly important that the present composition is administered to the infant in this period of life.
  • the present composition is therefore advantageously administered to a human of 0-24 months, more preferably to a human of 0-18 months, most preferably to a human of 0-12 months.
  • the present invention particularly aims to prevent disease development later in life and is preferably not a curative treatment.
  • the present composition is preferably administered to an infant not suffering from obesity or childhood obesity, particularly a non-obese infant more preferably an infant that does not suffer from overweight.
  • the present composition is preferably administered orally to the infant.
  • the composition aims to a) prevent and/or treat visceral adiposity and/or b) prevent and/or treat the accumulation of visceral fat mass to an excessive amount.
  • the present invention relates to a method for preventing visceral adiposity in a human with the age below 36 months.
  • the present invention also aims to prevent visceral adiposity at the age above 36 months, particularly to prevent visceral adiposity at the age above 8 years, particularly above 15 years.
  • the present inventors found that the present reduction in visceral adiposity suitably reduces occurrence and prevalence of disorders later in life, particularly disorders linked to visceral adiposity.
  • the present invention also provides a method for preventing the development of a disorder in a human with an age above 36 months, wherein said disorder is selected from the group consisting of diabetes (particularly type 2 diabetes), fasting hyperglycaemia, insulin resistance, hyperinsulinemia, hypertension, cardiovascular disease, visceral adiposity, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea, wherein the method comprises the administration of the present composition to an infant with an age below 36 months.
  • diabetes particularly type 2 diabetes
  • fasting hyperglycaemia insulin resistance
  • hyperinsulinemia hypertension
  • cardiovascular disease visceral adiposity
  • cerebrovascular disease arthrosclerosis
  • dyslipidaemia hyperuricaemia
  • fatty liver fatty liver
  • osteoarthritis sleep apnoea
  • dyslipidaemia includes the following diseases: hyperlipidaemia, hyperlipoproteinaemia, hyperchylomicronaemia, hypercholesteraemia, hypoalphalipoproteinemia hypoHDL/LDL-aemia and hypertriglyceridaemia.
  • diseases hyperlipidaemia, hyperlipoproteinaemia, hyperchylomicronaemia, hypercholesteraemia, hypoalphalipoproteinemia hypoHDL/LDL-aemia and hypertriglyceridaemia.
  • cardiovascular diseases particularly the development of diabetes, visceral adipocity and/or cardiovascular diseases can be prevented, more in particular cardiovascular diseases.
  • the present method is particularly suitable to prevent the abovementioned disorders during adolescence, in particular from 13 - 18 years and/or adulthood, in particular above 18 years.
  • the present prevention provides the use of a composition comprising a galactooligosaccharides and/or long chain polyunsaturated fatty acid (LC-PUFA) for the manufacture of a nutritional composition to be administered to a non-obese human with the age below 36 months and for preventing the development of a disorder when said human has an age above 36 months, wherein said disorder is selected from the group consisting of type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea.
  • LC-PUFA long chain polyunsaturated fatty acid
  • the galacto-oligosaccharide is preferably selected from the group consisting of transgalacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT.
  • the LC-PUFA is preferably DHA and/or EPA, preferably DHA and EPA.
  • the nutritional composition is preferably orally administered in the form of a complete nutritional formula.
  • the nutritional composition preferably comprises a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories.
  • the lipid component provides 35 to 55% of the total calories
  • the protein component provides 5 to 15% of the total calories
  • the digestible carbohydrate component provides 30 to 60% of the total calories.
  • Preferred amounts of galactooligosaccharides and/or LC-PUFA are described hereinabove.
  • Example 1 Programming effect of dietary fat on adult fat tissue
  • Offspring of C57/BL6 dams was standardized on postnatal day 2 to nests of 6 pups (4M and 2F) per dam. Dams were fed the experimental diet from day 2 onward until weaning. The lipid composition of the mouse milk reflects the fat composition of the diet. After weaning the male mice were housed in pairs and the experimental diet was continued until day 42 when all pups were fed the same diet containing lard and extra cholesterol (1%).
  • mice switched to a "cafeteria diet" comprising 10 wt.% fat (3 wt.% lard fat and lwt.% cholesterol) until day 98. The mice were weighed twice a week. The food intake was determined once a week during the entire experiment.
  • Table 3 Fat % development of total body mass in time and ratio's of subcutaneous (epididymal) and central (perirenal) fat.
  • Intragastric injection of water or a cellulose solution in water on day 1 served as control.
  • GOS fiber preparation consisted of 50% of digestible carbohydrates (mainly lactose), the two control injections were co-administered with carbohydrates to correct for this.
  • Table 4 Insulin and glucose levels levels in rats.
  • Example 3 Hydro lysed proteins beneficially affect insulin sensitivity
  • Protein preparations Intact whey protein, Deminal 90, and skimmed milk powder, were mixed to a 40 wt.% casein and 60 wt.% whey protein ratio. Hydrolyzed whey protein was obtained by hydrolysis of an acid whey preparation as described in examples 1-4 of WO 0141581. The degree of hydrolysis was 15%. Hydrolyzed casein was commercially obtained as LacProdan DI-2038 (Aria Foods). The two preparations were combined at a ratio of 40 wt.% hydrolyzed casein and 60 wt.% hydrolyzed whey.
  • Plasma insulin was measured by radioimmunoassay (RIA, of Linco Research) according to the manufacturer's instructions with the following adjustment: all assay volumes were reduced four times. Plasma glucose was measured with an oxidase-peroxidase method in 96-wells format (Roche Diagnostics, #1448668).
  • Table 5 Effects of intact and hydro lysed proteins on post-prandial peak time, maximal peak height and area under the curve of glucose and insulin.
  • Example 4 Infant nutrition Infant nutrition comprising a lipid component providing 48% of the total calories, a protein component providing 8% of the total calories and a digestible carbohydrate component providing 44% of the total calories; (i) the lipid component comprising based on total fatty acids: 10 wt.% LA; 20 wt.% MCFA; 0.2 wt.% DHA, 0.05 wt.% EPA; the LA/ ALA ratio is 5.1; (ii) the digestible carbohydrate component comprising 51 gram lactose/100 gram powder; 0.36 g galacto-oligosaccharides with DP 2-6 and 0.4 g fructo-oligosaccharides with DP 7-60; (ii) the protein component comprising cow milk protein.
  • the lipid component comprising based on total fatty acids: 10 wt.% LA; 20 wt.% MCFA; 0.2 wt.% DHA, 0.05 wt.% EPA; the LA/ ALA ratio is
  • the label of the package of this infant nutrition indicates that the nutrition prevents the development of one or more of the following disorders later- in- life: type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, artherosclerose, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and/or sleep apnoea.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pediatric Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a method for preventing and/or treating visceral adiposity by administering a certain nutritional composition to an infant with the age between 0 and 36 months, and preventing the occurrence of diseases later in life.

Description

Use of nutritional compositions for preventing disorders
FIELD OF THE INVENTION
The present invention relates to preventing diseases later in life by administering particular nutritional composition to infants with the age below 3 years.
BACKGROUND OF THE INVENTION
Breast-feeding is the preferred method of feeding infants. It has been suggested that breast feeding early in life might influence the occurrence of disorders later in life. However, there are circumstances that make breast-feeding impossible or less desirable. In those cases infant formula and follow-on formula are a good alternative. The composition of modern infant or follow-on formulas is adapted in such a way that it meets many of the special nutritional requirements of the fast growing and developing infant.
Still it seems that improvements can be made towards the constitution of infant milk formula. For example little is known about the effects of ingredients in the infant formula on health later in life. The present invention relates to such future health.
WO 2005063050 describes a method of increasing lean body mass and reducing fat body mass in infants by administering to an infant, term or preterm, a nutritional formula comprising a source of DHA and ARA. WO 2006057551 relates to an infant nutrition comprising at least one protease inhibitor, a process for preparing such an infant nutrition and use of the infant nutrition for the treatment and/or prevention of childhood obesity and secondary disorders resulting from childhood obesity. WO 03005836 describes dietary products for infant, child and adult nutrition which possess adequate levels and ratios of medium chain fatty acids and omega- polyunsaturated fatty acids. Consumption of these dietary products can contribute to the prevention of obesity in developing individuals and can contribute to a reduction in body fat mass in individuals who are trying to loose weight or reduce body fat mass (e.g., obese individuals). WO 2006069918 describes a method of continuously reducing the circulating level of insulin like growth factor 1 (IGF-I) in the first few months of the life of an infant by administering to the infant a nutritional composition comprising proteins in an amount such that the composition contains less than 2.25g of protein per lOOkcal. As IGF-I is known to be a key control point in nutritional regulation of growth, this may offer a method of reducing the risk of developing obesity later life. Aillaud et al, 2006, Progress in Lipid research 45:203-206, discusses the role of n6 polyunsaturated fatty acids in the excessive adipose tissue development and relationship to obesity.
SUMMARY OF THE INVENTION
The present inventors have recognized certain gaps in the present knowledge on the relation between nutrition in early infancy and the development of diseases later in life.
The present inventors have determined that the whole adipose tissue mass of infants is not a good predictor to determine the risks of diseases later in life. Body fat can be distributed and stored in fat tissue at different places within the body. Different fat tissues have different metabolic effects, particularly in infants. Subcutaneous fat in infants has the important function to maintain an adequate body temperature. Fat deposited in the central part of the body (visceral fat) serves only as storage of energy. Moreover, adipose cells at different locations differ in size and in their protein secretion profile which are potential regulators of glucose and lipid homeostasis. Importantly, visceral fat mass is a highly metabolically active tissue that releases free fatty acids directly into the hepatic portal vein. The obtained free fatty acid fluxes have an impact on glucose metabolism and insulin sensitivity of the liver and subsequently can lead to metabolic disorders. Therefore, a main contributor of the development of certain disorders later in life appeared to be the visceral fat mass development in early infancy (visceral adiposity in early infancy). Visceral fat mass accumulation was found to be a main contributor of development disorders, particularly of metabolic and cardiovascular disorders, independent of overall obesity. Hence, subsequent to this finding it is the aim of the present invention to prevent disorders later in life and reduce visceral fat adipocyte formation in infancy.
It was found that in early infancy, and to a lesser extent during puberty, visceral adipocyte count is determined. In the other stages of life visceral fat mass is "only" increased through filling of the adipocytes with fat. Cell numbers remain approximately the same throughout adult life. Hence, it is highly desirable to reduce visceral adipocyte proliferation in early infancy without excessively reducing subcutaneous fat mass. Reduced visceral adipocyte count prevents disorders later in life.
Finding adequate measures to modify visceral adipocyte proliferation in infants is particularly difficult, as administration of pharmaceutical compounds is generally unacceptable and nutrition cannot be rigorously modified because the infant needs to receive sufficient nutrients for normal growth and development. Furthermore, a- specific reduction of fat mass can be disadvantageous, e.g. because the subcutaneous fat mass has the important role of maintaining body temperature. Hence, a main aim of the present invention is to reduce the development of visceral fat mass accumulation in an infant and/or later in life by designing a nutrition to be administered to the infant which ensures maintenance of normal growth and development.
The present inventors found a nutritional composition which reduced visceral adiposity and other disorders later in life, particularly diabetes (particularly type 2 diabetes), fasting hyperglycaemia, insulin resistance, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea.
The inventors experimentally evidenced that early-in-life administering nutrition wherein the lipid component is relatively low in linoleic acid (LA) and with a low linoleic acid/alpha- lino lenic acid (L A/ AL A) ratio, results in a decreased visceral fat mass accumulation and/or visceral adiposity, particularly results in a decreased visceral fat mass accumulation and/or visceral adiposity later in life. In the experiments, rodents received a specific nutrition (low LA, low LA/ ALA ratio) early- in-life (via the nursing mother), while a control group did not receive the specific nutrition. At the later-in-life stage the animal groups received the same diet high in saturated fat. Surprisingly, not only a decrease in total body fat was observed in rodents which had been fed this experimental nutrition, but also a specific decrease in visceral fat mass, i.e. a decreased visceral adiposity, was observed. This is indicative for the effect of the present composition in the development of diseases later in life, particularly during childhood (age 3-12), adolescence (age 13-18) and adulthood (age above 18).
In a further aspect it was also found that long chain polyunsaturated fatty acids (LC- PUFA), particularly the n3 LC-PUFA docosahexaenoic acid (DHA), stearidonic acid (SDA), docosapentaenoic acid (DPA) and/or eicosapenteenoic acid (EPA), also reduced the visceral fat mass accumulation while maintaining normal growth and development. LC-PUFA are therefore advantageously incorporated in compositions for reducing visceral adiposity and/or disorders later in life. Medium chain fatty acids (MCFA) did not specifically reduce visceral adiposity, but resulted in an overall reduced fat content later in life. MCFA are therefore advantageously included in the present composition, but in a limited amount. Furthermore, the inclusion of MCFA is particularly desirable in the present low LA formula as it prevents LA deficiency.
DETAILED DESCRIPTION OF THE INVENTION
In one embodiment the present invention concerns the use of a composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories, wherein the lipid component comprises (i) linoleic acid (LA) and alpha- lino lenic acid (ALA) in a weight ratio of LA/ ALA between 2 and 6; (ii) less than 14.5 wt.% LA based on total fatty acids; (iii) long chain polyunsaturated fatty acids (LC-PUFA); and optionally (iv) 10-50 wt.% medium chain fatty acids (MCFA) for the manufacture of a nutritional composition to be administered to a non- obese human with the age below 36 months and for preventing the development of a disorder when said human has an age above 36 months, wherein said disorder is selected from the group consisting of type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea.
In one embodiment the present invention concerns the use of a composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 60% of the total calories, wherein the lipid component comprises less than 14.5 wt.% linoleic acid based on total fatty acids and a weight ratio of linoleic acid (LA) to alpha- lino lenic acid (ALA) between 2 and 6, for the manufacture of a nutritional composition for a) preventing and/or treating visceral adiposity and/or b) preventing and/or treating the accumulation of visceral fat mass to an excessive amount wherein the nutritional composition is administered to an infant with the age between 0 and 36 months.
The present invention also concerns a composition to be administered to a non-obese human with the age below 36 months, said composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories, wherein the lipid component comprises (i) linoleic acid (LA) and alpha- linolenic acid (ALA) in a weight ratio of LA/ ALA between 2 and 6; (ii) less than 14.5 wt.% LA based on total fatty acids; (iii) long chain polyunsaturated fatty acids (LC- PUFA); and optionally (iv) 10-50 wt.% medium chain fatty acids (MCFA) for preventing the development of a disorder when said human has an age above 36 months, wherein said disorder is selected from the group consisting of type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea.
The present invention also concerns a composition to be administered to an infant with the age between 0 and 36 months, said composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories, wherein the lipid component comprises less than 14.5 wt.% linoleic acid based on total fatty acids and a weight ratio of linoleic acid (LA) to alpha- lino lenic acid (ALA) between 2 and 6, for a) preventing and/or treating visceral adiposity and/or b) preventing and/or treating the accumulation of visceral fat mass to an excessive amount. Visceral adiposity
The term 'visceral adiposity' refers to a condition with increased visceral fat mass. The term visceral adiposity is also referred to as central obesity. Visceral adiposity is typically caused by (accumulation of) excessive visceral fat mass. Visceral fat, also known as organ fat, intra-abdominal fat, peritoneal fat or central fat is normally located inside the peritoneal cavity as opposed to subcutaneous fat which is found underneath the skin and intramuscular fat which is found interspersed in skeletal muscles. Visceral fat includes mesenteric fat, perirenal fat and retroperitoneal fat. Visceral fat stores can suitably be investigated by imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI) and ultrasonography. An adult is considered to suffer from visceral adiposity or to have accumulated visceral fat mass to an excessive amount when at the umbilicus level the visceral adipose tissue (VAT) exceeds 100 cm2 in man, or 90 cm2 in women (Saito et al, 1009, Int J Obes Suppl 3:S226). Infants generally have about 10% visceral fat mass based on total fat mass. The term visceral adiposity in infants therefore preferably relates to a situation wherein the visceral fat mass exceeds about 10 wt.% based on total fat (e.g. between 10 and 20 wt.% visceral fat mass based on total fat mass). In humans beyond infancy, particularly of or above the age of 12 years, visceral adiposity is also referred to as 'apple-shaped' obesity, 'android' obesity, 'abdominal' obesity, 'male-type' obesity, 'waist-predominant' obesity, 'truncal' obesity or 'masculine' obesity. A waist circumference above 102 cm in adult man or above 88 cm in adult women indicates visceral adiposity. Also a waist-hip ratio can be used as indicator for visceral adiposity. Hip-waist ratio's exceeding 0.9 in man and 0.85 in women indicate visceral adiposity. For children of 3-19 years old appropriate cutoffs for age- and sex-dependent waist circumferences can be found in Taylor et al, 2000 Am J Clin Nutr 72:490-495. A subject suffers from visceral adiposity when it meets one or more of the above criteria (regarding VAT, waist circumference or waist-hip ratio treshholds). Accumulation of visceral fat mass to an excessive amount relates to the accumulation of visceral fat mass to a level at which visceral adiposity occurs and can be determined by the same methods as described above for visceral adiposity. Total fat mass can be determined by DEXA (dual-energy X-ray absorptiometry). The present composition is preferably administered to a non-obese human with the age below 36 months, preferably to a non-overweight human with the age below 36 months. Obesity and/or overweight can suitably be determined by a physician. Typically, a non-obese infant below 36 months of age has gender specific weight-for -length below the 95th percentile, more preferably below the 85th percentile. Gender specific weight-for-length percentiles have been published by Center for Disease Control and Prevention (CDC) in 2000.
Lipid component Herein LA refers to linoleic acid (18:2 n6); ALA refers to alpha- lino lenic acid (18:3 n3); LC-PUFA refers to long chain polyunsaturated fatty acids comprising at least 20 carbon atoms in the fatty acid chain and with 2 or more unsaturated bonds; DHA refers to docosahexaenoic acid (22:6, n3); EPA refers to eicosapentaenoic acid (20:5 n3); ARA refers to arachidonic acid (20:4 n6); Medium chain fatty acids (MCFA) are fatty acids and/or acyl chains with a chain length of 6, 8 or 10 carbon atoms. MCFA may also be referred to as medium chain triglycerides (MCT).
The present inventors have found that specific compositions that have a low LA/ ALA ratio and that are low in LA and that optionally comprise LC-PUFA and optionally comprise MCFA prevent the occurrence of visceral adiposity. Particularly the administration of a nutritional composition comprising (i) a LA/ ALA ratio between 2 and 6 and (ii) a low LA content (<14.5 wt.% based on total fatty acids) and optionally LC-PUFA (particularly DHA) resulted in a decrease in visceral adiposity later in life and/or a reduced occurrence of disorders later in life. MCFA were found to reduce adiposity in general. This finding further enables the development of an optimal composition, which comprises MCFA, but not in excessive amounts, i.e. between 10 and 50 wt.% based on total weight of fatty acids.
The present composition comprises lipid. LA should be present in a sufficient amount in order to promote a healthy growth and development, yet in an amount as low as possible to prevent occurrence of visceral adiposity. The composition therefore comprises less than 14.5 wt.% LA based on total fatty acids, preferably between 5 and 14.5 wt.%, more preferably between 6 and 12 wt.%. Based on total dry weight of the composition the present composition preferably comprises 2 to 5 wt.% LA. When in liquid form, e.g. as ready-to-drink formula, the LA content is preferably between 0.3 and 0.55 g LA per 100 ml of the liquid composition. The LA preferably provides between 4 to 8% of total calories in the present composition.
ALA should be present in a sufficient amount to promote a healthy growth and development of the infant. The present composition therefore preferably comprises at least 1.6 wt.% ALA based on total fatty acids, preferably between 1.6 and 5 wt.% ALA. Based on total dry weight of the composition the present composition preferably comprises at least 0.30 wt.% ALA, preferably between 0.3 and 1 wt.% ALA. When in liquid form, e.g. as ready-to-drink formula, the ALA content is preferably at least 50 mg ALA per 100 ml of the liquid composition, preferably between 50 and 150 mg ALA per 100 ml.
The weight ratio LA/ ALA should be well balanced in order to prevent visceral fat mass deposition (e.g. visceral adiposity) and disorders later in life, while at the same time ensure a normal growth and development. The proper ratio was found by the present inventors. The present composition comprises a weight ratio of LA/ALA between 2 and 6, more preferably between 3 and 6, even more preferably between 4 and 5.5, even more preferably between 4 and 5. The lipid component comprises less than 14.5 wt.% LA based on total fatty acids and a LA/ ALA ratio of 2 to 6.
Preferably the present composition comprises LC-PUFA. The present inventors found that LC-PUFA reduces visceral adiposity later in life. More preferably, the present composition comprises n-3 LC-PUFA, even more preferably EPA, SDA, DPA and/or DHA. It was found that these LC-PUFA decrease the visceral adiposity.
Since a low concentration of DHA, SDA, DPA and/or EPA is already effective and normal growth and development are important, the content of LC-PUFA in the present composition, preferably does not exceed 15 wt.% of the total fat content, preferably does not exceed 10 wt.%, even more preferably does not exceed 5 wt.%. Preferably the present composition comprises at least 0.1 wt.%, preferably at least 0.25 wt.%, more preferably at least 0.5 wt.%, even more preferably at least 0.75 wt.% LC-PUFA of the total fat content. For the same reason, the EPA content preferably does not exceed 5 wt.% of the total fat, more preferably does not exceed 1 wt.%, but is preferably at least 0.025 wt.%, more preferably at least 0.05 wt.% of the total fat. The DHA content preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.%, but is at least 0.1 wt.% of the total fat. The DPA content preferably does not exceed 1 wt.%, more preferably does not exceed 0.5 wt.% of the total fat, but is preferably at least 0.01 wt.% of the total fat. The SDA content preferably does not exceed 0.5 wt.%, more preferably does not exceed 0.25 wt.% of the total fat, but is at least 0.005 wt.% of the total fat.
As arachidonic acid (ARA, an n6 PUFA) counteracts the effect, the present composition comprises relatively low amounts or ARA. The ARA content preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.%, more preferably; does not exceed 0.5 wt.%, even more preferably does not exceed 0.25 wt.%, most preferably does not exceed 0.05 wt.% based on total fatty acids. The LC-PUFA, LA and/or ALA may be provided as free fatty acids, in triglyceride form, in diglyceride form, in monoglyceride form, in phospholipid form, or as a mixture of one of more of the above. Preferably the present composition contains LC-PUFA in triglyceride and/or phospholipid form.
Medium chain fatty acids (MCFA) are fatty acids and/or acyl chains with a chain length of 6, 8 or 10 carbon atoms. The present low LA and low LA/ ALA composition advantageously comprises 10-50 wt.% MCFA based on total fatty acids. LA is an essential fatty acid, meaning that it cannot be synthesized within the body. As the present composition comprises a relatively low LA content, it is important that the LA included in the present composition is not converted to energy (by fat oxidation) and therefore not available for anabolic purposes. To reduce the oxidation of LA in the present low LA composition MCFA can suitably be added. MCFA are easily mobilized in the bloodstream to provide long-lasting energy, rather than being stored as fat and thereby reduce LA oxidation.
The present inventors also found that MCFA contribute to a reduced fat mass later in life. Therefore the present composition advantageously comprises MCFA. However, the MCFA reduce the accumulation of fat but were found to have no specific effect on visceral fat mass reduction. Therefore, the present composition preferably comprises 10 to 50 wt.% MCFA based on total fatty acids, more preferably 20 to 40 wt.%. Preferably the present composition contains at least one, preferably at least two lipid sources selected from the group consisting of linseed oil (flaxseed oil), rape seed oil (including colza oil, low erucic acid rape seed oil and canola oil), salvia oil, perilla oil, purslane oil, lingonberry oil, sea buckthorn oil, hemp oil, high oleic sunflower oil, high oleic safflower oil, olive oil, marine oils, microbial oils, black currant seed oil, echium oil, butter fat, coconut oil and palm kernel oil. Preferably the present composition contains at least one, preferably at least two lipid sources are selected from the group consisting of linseed oil, rapeseed oil, coconut oil, high oleic sunflower oil, butter oil and marine oil.
Table 1 gives preferred characteristics of the lipid component of the present composition
TABLE 1
Figure imgf000011_0001
Non-digestible oligosaccharides
One effect of the visceral fat mass is believed to be the stimulation of insulin production, with can result over time in a reduced insulin sensitivity and other disorders and other metabolic disorders. High blood insulin levels stimulate glucose uptake in adipose tissue, resulting in an increased adipose tissue mass. In infants the high insulin levels contributes to increased proliferation of visceral adipocytes, at least partly due to the increased glucose uptake.
The present composition therefore preferably maintains low insulin levels. The present composition preferably comprises an ingredient which increases and/or maintains insulin sensitivity. It was found that non-digestible oligosaccharides (NDO) that can be fermented (particularly galacto-oligosaccharides) have a blood insulin tempering effect, and consequently contributes to a reduced proliferation of visceral adipocytes. Additionally it was also recognised that infants ingest more calories when bottle fed compared to a situation where breast feeding occurs. In addition to the compositional features of the lipid component as suggested in the present invention, the effectiveness can further be improved by reducing caloric intake. Limiting dosage of the nutritional composition is however not a feasible option for infants. The present inventors have found that advantageously the present composition comprises non- digestible oligosaccharides.
Therefore, the present composition preferably comprises the present lipid component and a non-digestible oligosaccharide which can be fermented. The combination of the present lipid component and the non-digestible oligosaccharides synergistically reduces the visceral adiposity and/or prevents the development of disorders later in life. Preferably the non-digestible oligosaccharides have a DP between 2 and 60. The composition preferably prevents the onset of insulin resistance. The non-digestible oligosaccharide is preferably selected from the group consisting of fructo- oligosaccharides (including inulin), galacto-oligosaccharides (including transgalacto- oligosaccharides), gluco-oligosaccharides (including gentio-, nigero- and cyclodextrin-oligosaccharides), arabino-oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides. Preferably the present composition comprises fructo-oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably galacto-oligosaccharides, most preferably transgalacto-oligosaccharides. In a preferred embodiment the composition comprises a mixture of transgalacto-oligosaccharides and fructo-oligosaccharides. Preferably the present composition comprises galacto-oligosaccharides with a DP of 2-10 and/or fructooligosaccharides with a DP of 2-60. The galacto-oligosaccharide is preferably selected from the group consisting of transgalacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT. In a particularly preferred embodiment the present method comprises the administration of transgalacto-oligosaccharides ([galactose]n-glucose; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, ...., 59 ,60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10). Transgalacto-oligosaccharides (TOS) are for example sold under the trademark Vivinal™ (Borculo Domo Ingredients, Netherlands). Preferably the saccharides of the transgalacto-oligosaccharides are β- linked. Fructo-oligosaccharide is a NDO comprising a chain of β linked fructose units with a DP or average DP of 2 to 250, more preferably 10 to 100. Fructo- oligosaccharide includes inulin, levan and/or a mixed type of polyfructan. An especially preferred fructo-oligosaccharide is inulin. Fructo-oligosaccharide suitable for use in the compositions is also already commercially available, e.g. Raftiline®HP (Orafti). Uronic acid oligosaccharides are preferably obtained from pectin degradation. Hence the present composition preferably comprises a pectin degradation product with a DP between 2 and 100. Preferably the pectin degradation products is prepared from apple pectin, beet pectin and/or citrus pectin. Preferably the composition comprises transgalacto-oligosaccharide, fructo-oligosaccharide and pectin degradation product. The weight ratio transgalacto-oligosaccharide : fructo- oligosaccharide : pectin degradation product is preferably 20-2 : 1 : 1-3, more preferably 12-7 : 1 : 1-2.
Lactose
The maintenance of insulin sensitivity can be further improved by inclusion of a low glycaemic carbohydrate in the present composition, preferably lactose. Hence, the present composition preferably comprises in addition to the present lipid component, non-digestible oligosaccharides and/or lactose. The present composition preferably comprises a digestible carbohydrate component, wherein at least 35 wt.%, more preferably at least 50 wt.%, more preferably at least 75 wt.%, even more preferably at least 90 wt.%, most preferably at least 95 wt.% is lactose. The present composition preferably comprises at least 25 grams lactose per 100 gram dry weight of the present composition, preferably at least 40 grams lactose/100 gram.
Hydrolyzed protein
Preferably the composition comprises hydrolyzed casein and/or hydrolyzed whey protein. It was found that administration of a composition wherein the protein comprises hydrolyzed casein and hydrolyzed whey results in reduced post-prandial levels of both insulin and glucose compared to the administration of a composition comprising intact casein and intact whey protein. Increased levels of both insulin and glucose indicate a form of insulin resistance in formula fed infants, which is believed contribute to the development of visceral adiposity later- in- life. The present composition preferably comprises at least 25 wt.% peptides with a chain length of 2 to 30 amino acids based on dry weight of protein. The amount of peptides with a chain length between 2 and 30 amino acids can for example be determined as described by de Freitas et al, 1993, J. Agric. Food Chem. 41:1432-1438. The present composition preferably comprises casein hydro lysate and/or whey protein hydro lysate, more preferably casein hydro lysate and whey protein hydro lysate because the amino acid composition of bovine casein is more similar to the amino acid composition found in human milk protein and whey protein is easier to digest and found in greater ratios in human milk. The composition preferably comprises at least 50 wt.%, preferably at least 80 wt.%, most preferably about 100 wt.% of a protein hydrolysate, based on total weight of the protein. The present composition preferably comprises a protein with a degree of hydrolysis of the protein between 5 and 25%, more preferably between 7.5 and 21%, most preferably between 10 and 20%. The degree of hydrolysis is defined as the percentage of peptide bonds which have been broken down by enzymatic hydrolysis, with 100% being the total potential peptide bonds present. The present composition preferably contains 1.5 to 2.25 g protein/100 kcal, preferably between and 1.8 and 2.0 g/100 kcal.
Casein Casein is advantageously present since it increases the gastric emptying times by forming a curd in the stomach, thereby increasing satiety. As satiety induction is highly desirable, see above, the present composition preferably comprises casein. When the composition is in liquid form, e.g. as a ready-to-drink liquid, the composition preferably comprises at least 0.5 g casein per 100 ml, preferably between 0.5 and 5 gram casein per 100 ml. Preferably the composition comprises at least 4 wt.% casein based on dry weight. Preferably the casein is intact and/or non- hydro lyzed.
Nutritional composition The present composition is particularly suitable for providing the daily nutritional requirements to an infant with the age below 36 months, particularly an infant with the age below 24 months, even more preferably an infant with the age below 12 months. Hence, the present composition comprises a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories. Preferably the present composition comprises a lipid component providing 40 to 50 % of the total calories, the protein component provides 6 to 12% of the total calories and the digestible carbohydrate component provides 40 to 50% of the total calories. When in liquid form, e.g. as a ready-to-feed liquid, the composition preferably comprises 2.1 to 6.5 g fat per 100 ml, more preferably 3.0 to 4.0 g perl 00 ml. Based on dry weight the present composition preferably comprises 12.5 to 40 wt.% fat, more preferably 19 to 30 wt.%.
The amount of saturated fatty acids is preferably below 58 wt.% based on total fatty acids, more preferably below 45 wt.%. The concentration of monounsaturated fatty acids preferably ranges from 17 to 60% based on weight of total fatty acids. The present composition is not human breast milk. The present composition preferably comprises (i) vegetable lipid and/or animal (non-human) fat; and/or (ii) vegetable protein and/or animal (non-human) milk protein. Examples of animal milk protein are whey protein from cows milk and protein from goat milk. Preferably the present composition does not comprise a proteinase inhibitor, preferably not a trypsin inhibitor, chymotrypsin inhibitor or elastase inhibitor.
The present composition preferably comprises at least 50 wt.% protein derived from non-human milk based on total protein, more preferably at least 90 wt.%. Preferably the present composition comprises at least 50 wt.% cow milk derived protein based on total protein, more preferably at least 90 wt.%. Preferably the present composition comprises acid whey and/or sweet whey with a reduced concentration of glycomacropeptide. Preferably the present composition comprises protein derived from β-casein and/or α-lactalbumin. The present composition preferably comprises casein and whey proteins in a weight ratio casein:whey of 10:90 to 90:10, more preferably 20:80 to 80:20. The term protein as used in the present invention refers to the sum of proteins, peptides and free amino acids.
The present composition is preferably administered in liquid form. In order to meet the caloric requirements of the infant, the composition preferably comprises 50 to 200 kcal/100 ml liquid, more preferably 60 to 90 kcal/100 ml liquid, even more preferably 60 to 75 kcal/100 ml liquid. This caloric density ensures an optimal ratio between water and calorie consumption. The osmolarity of the present composition is preferably between 150 and 420 mOsmol/1, more preferably 260 to 320 mOsmol/1. The low osmolarity aims to reduce the gastrointestinal stress. Stress can induce adiposite formation.
Preferably the composition is in a liquid form, with a viscosity below 35 cps as measured in a Brookfield viscometer at 20°C at a shear rate of 100 s"1. Suitably, the composition is in a powdered from, which can be reconstituted with water to form a liquid, or in a liquid concentrate form, which should be diluted with water.
When the composition is a liquid form, the preferred volume administered on a daily basis is in the range of about 80 to 2500 ml, more preferably about 450 to 1000 ml per day.
Infant
Visceral adipocytes proliferate during the first 36 months of life as well as (more limited) in puberty. Hence the present composition is administered to the infant during the first 3 years of life. It was found that there is a predominance of proliferation of visceral adipocytes in the first 12 months of life (optimum in perinatal adipocyte proliferation). Hence, it is particularly important that the present composition is administered to the infant in this period of life. The present composition is therefore advantageously administered to a human of 0-24 months, more preferably to a human of 0-18 months, most preferably to a human of 0-12 months. The present invention particularly aims to prevent disease development later in life and is preferably not a curative treatment. Hence, the present composition is preferably administered to an infant not suffering from obesity or childhood obesity, particularly a non-obese infant more preferably an infant that does not suffer from overweight. The present composition is preferably administered orally to the infant.
Application
The composition aims to a) prevent and/or treat visceral adiposity and/or b) prevent and/or treat the accumulation of visceral fat mass to an excessive amount. Particularly, the present invention relates to a method for preventing visceral adiposity in a human with the age below 36 months. The present invention also aims to prevent visceral adiposity at the age above 36 months, particularly to prevent visceral adiposity at the age above 8 years, particularly above 15 years. The present inventors found that the present reduction in visceral adiposity suitably reduces occurrence and prevalence of disorders later in life, particularly disorders linked to visceral adiposity. The present invention also provides a method for preventing the development of a disorder in a human with an age above 36 months, wherein said disorder is selected from the group consisting of diabetes (particularly type 2 diabetes), fasting hyperglycaemia, insulin resistance, hyperinsulinemia, hypertension, cardiovascular disease, visceral adiposity, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea, wherein the method comprises the administration of the present composition to an infant with an age below 36 months. The term dyslipidaemia includes the following diseases: hyperlipidaemia, hyperlipoproteinaemia, hyperchylomicronaemia, hypercholesteraemia, hypoalphalipoproteinemia hypoHDL/LDL-aemia and hypertriglyceridaemia. Particularly the development of diabetes, visceral adipocity and/or cardiovascular diseases can be prevented, more in particular cardiovascular diseases. The present method is particularly suitable to prevent the abovementioned disorders during adolescence, in particular from 13 - 18 years and/or adulthood, in particular above 18 years.
Galactooligosaccharides and/or LC-PUFA
The present prevention provides the use of a composition comprising a galactooligosaccharides and/or long chain polyunsaturated fatty acid (LC-PUFA) for the manufacture of a nutritional composition to be administered to a non-obese human with the age below 36 months and for preventing the development of a disorder when said human has an age above 36 months, wherein said disorder is selected from the group consisting of type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea. The galacto-oligosaccharide is preferably selected from the group consisting of transgalacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT. The LC-PUFA is preferably DHA and/or EPA, preferably DHA and EPA. The nutritional composition is preferably orally administered in the form of a complete nutritional formula. Hence, the nutritional composition preferably comprises a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories. Preferred amounts of galactooligosaccharides and/or LC-PUFA are described hereinabove.
In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one".
EXAMPLES
Example 1: Programming effect of dietary fat on adult fat tissue
Offspring of C57/BL6 dams was standardized on postnatal day 2 to nests of 6 pups (4M and 2F) per dam. Dams were fed the experimental diet from day 2 onward until weaning. The lipid composition of the mouse milk reflects the fat composition of the diet. After weaning the male mice were housed in pairs and the experimental diet was continued until day 42 when all pups were fed the same diet containing lard and extra cholesterol (1%).
The experimental diets that were used were: 1) LC-PUFA diet (tuna fish oil); 2) Low LA diet (butter oil; low in canola oil, high in Trisun 80, no palm oil); 3) MCFA diet; 4) control diet (similar amounts of canola oil, coconut oil and palm oil). The fatty acid composition of the diets is presented in Table 2. At day 42, all mice switched to a "cafeteria diet" comprising 10 wt.% fat (3 wt.% lard fat and lwt.% cholesterol) until day 98. The mice were weighed twice a week. The food intake was determined once a week during the entire experiment. To determine body composition (i.e., fat mass (FM) and fat-free mass (FFM)) DEXA scans (Dual Energy X-ray Absorbiometry) were performed under general anesthesia at 6, 10 and 14 weeks of age, 42, 70 and 98 days after birth respectively, by densitometry using a PIXImus imager (GE Lunar, Madison, WI, USA). At the age of 14 weeks the male mice were sacrified and plasma, epididymal fat, perirenal fat, pancreas, liver and kidneys were dissected and weighed.
Figure imgf000019_0001
Results: No effect on growth and food intake was observed during the experimental period between the groups (data not shown). Moreover, the development of fat mass (determined with DEXA) was not different at day 42 (end of the diet intervention period). However, a subsequent treatment with a cafetaria diet (high in saturated fatty acids) between day 42 and day 98 of all groups resulted in clear differences in body composition at the end of the experiment (day 98), see Table 3. The fat mass was reduced when the pups received a LC-PUFA, MCFA or low LA diet in their early life, compared to the control diet. Moreover, the diets in the early life had markedly effect on the body fat distribution. It was shown that the ratio of the subcutaneous:visceral fat (measured by epididymal and perirenal fat, respectively) in adult mice at day 98 was increased by 14% in the LC-PUFA group and 32% in the low LA group, but was not increased in the MCFA group compared to the control group, see Table 3. This demonstrated that the visceral fat mass in later life clearly is decreased by an early in life diet high in LC-PUFA and/or low in LA and/or low LA/ALA. So, it is concluded that these fat compositions program and/or imprint the body to get a healthier body fat composition later in life.
Table 3: Fat % development of total body mass in time and ratio's of subcutaneous (epididymal) and central (perirenal) fat.
Figure imgf000020_0001
Example 2: Blood glucose/insulin and non-digestible oligosaccharides Animals and treatment: Adult male Wistar rats (n=7) were given a GOS fiber load, cellulose load or water via a gastric canula on day 1. A 6 mL bolus load was administered equal to 50% of their daily fiber intake; GOS fiber used was transgalacto-oligosaccharides obtained from Elix'or (Borculo Domo). Fiber was dissolved in water. About 24 h later (on day 2) an oral glucose tolerance test was carried out and the postprandial glucose and insulin course was monitored for 120 min upon the intragastric injection of a carbohydrate load (2 g/kg body weight). To this end blood samples were drawn repeatedly via a jugular vein canula. Intragastric injection of water or a cellulose solution in water on day 1 served as control. As the GOS fiber preparation consisted of 50% of digestible carbohydrates (mainly lactose), the two control injections were co-administered with carbohydrates to correct for this.
Results: pre-treatment with GOS fibers clearly decreased the amount of insulin secreted, resulting in significant (p<0.05) lower incremental AUC values. Blood glucose levels were not affected significantly. Pre-treatment with cellulose or water did not modulate the insulin secretion, see Table 4.
Table 4: Insulin and glucose levels levels in rats.
Pre-treatment with: AUC insulin (pM*30 AUC glucose min) (mM*30 min)
Water 41 ± 7 69 ± 10
Cellulose 46 ± 8 75 ± 9
GOS 22 ± 4 74 ± 15
Example 3: Hydro lysed proteins beneficially affect insulin sensitivity Protein preparations: Intact whey protein, Deminal 90, and skimmed milk powder, were mixed to a 40 wt.% casein and 60 wt.% whey protein ratio. Hydrolyzed whey protein was obtained by hydrolysis of an acid whey preparation as described in examples 1-4 of WO 0141581. The degree of hydrolysis was 15%. Hydrolyzed casein was commercially obtained as LacProdan DI-2038 (Aria Foods). The two preparations were combined at a ratio of 40 wt.% hydrolyzed casein and 60 wt.% hydrolyzed whey.
Methods: 20 adult male Wistar rats (aged 10 weeks at the start of the experiment) were housed individually. After a 4 h fasting period, 10 animals were fed 2 ml of a composition. Three different compositions were tested in a cross-over design (experiments separated by one week). I) human breast milk, ii) 17 mg whey/casein protein and 86 mg lactose per ml. iii) 17 mg hydrolyzed whey and hydrolyzed casein and 86 mg lactose per ml. Subsequently, blood samples (200 μl) were collected in heparinised chilled tubes at t=0, 5, 10, 15, 30, 60, 90, and 120 minutes after feeding. Subsequently, plasma was separated after centrifugation (10 min, 5000 rpm) and stored at -20 0C untill analysis. Plasma insulin was measured by radioimmunoassay (RIA, of Linco Research) according to the manufacturer's instructions with the following adjustment: all assay volumes were reduced four times. Plasma glucose was measured with an oxidase-peroxidase method in 96-wells format (Roche Diagnostics, #1448668).
Results: The post-prandial peak of glucose as well as of insulin was lower in rats fed intact whey and intact casein than in rats fed hydrolyzed whey and hydrolyzed casein. The area under the curve (AUC) of insulin and glucose is lower in rats fed hydrolyzed whey and hydrolyzed casein than in rats fed intact whey and intact casein. Also the peak time, maximal peak height, and AUC was lowered when hydrolyzed proteins were consumed (Table 5). The presence of a hydrolyzed proteins resulted in post- prandial blood glucose as well as insulin levels and kinetics more similar to those observed with human milk. Decreased levels of both insulin and glucose indicate increased insulin sensitivity, which is believed contribute to the prevention of central obesity later-in-life.
Table 5: Effects of intact and hydro lysed proteins on post-prandial peak time, maximal peak height and area under the curve of glucose and insulin.
Effect Intact proteins Hydrolysed proteins Human milk
Peak time (m ± se)
Glucose 20.0 ± 12.7 11.50 ± 2.6 12.0 ± 2.4
Insulin 8.3 ± 0.8 8.33 ± 1.4 11.7 ± 1.2
Maximal peak height (g/1 ± se)
Glucose 0.46 ± 1.0 0.31 ± 0.07 0.33 ± 0.08
Insulin 1.51 ± 0.44 1.11 ± 0.20 1.41 ± 0.27
AUC 30 ( ± se)
Glucose (mM*30min)5.9 ± 1.6 5.08 ± 1.4 5.1 ± 1.8
Insulin (pM*30min) 14.3 ± 3.4 12.63 ± 4.6 11.7 ± 4.7
Example 4: Infant nutrition Infant nutrition comprising a lipid component providing 48% of the total calories, a protein component providing 8% of the total calories and a digestible carbohydrate component providing 44% of the total calories; (i) the lipid component comprising based on total fatty acids: 10 wt.% LA; 20 wt.% MCFA; 0.2 wt.% DHA, 0.05 wt.% EPA; the LA/ ALA ratio is 5.1; (ii) the digestible carbohydrate component comprising 51 gram lactose/100 gram powder; 0.36 g galacto-oligosaccharides with DP 2-6 and 0.4 g fructo-oligosaccharides with DP 7-60; (ii) the protein component comprising cow milk protein. The label of the package of this infant nutrition indicates that the nutrition prevents the development of one or more of the following disorders later- in- life: type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, artherosclerose, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and/or sleep apnoea.

Claims

1. Use of a composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories, wherein the lipid component comprises (i) linoleic acid (LA) and alpha- lino lenic acid (ALA) in a weight ratio of LA/ ALA between 2 and 6; (ii) less than 14.5 wt.% LA based on total fatty acids; (iii) long chain polyunsaturated fatty acids (LC-PUFA); and optionally (iv) 10-50 wt.% medium chain fatty acids (MCFA) for the manufacture of a nutritional composition to be administered to a non-obese human with the age below 36 months and for preventing the development of a disorder when said human has an age above 36 months, wherein said disorder is selected from the group consisting of type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea.
2. Use of a composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component provides 35 to 55% of the total calories, the protein component provides 5 to 15% of the total calories and the digestible carbohydrate component provides 30 to 60% of the total calories, wherein the lipid component comprises less than 14.5 wt.% linoleic acid based on total fatty acids and a weight ratio of linoleic acid (LA) to alpha- lino lenic acid (ALA) between 2 and 6, for the manufacture of a nutritional composition for a. preventing and/or treating visceral adiposity b. preventing and/or treating the accumulation of visceral fat mass to an excessive amount wherein the nutritional composition is administered to an infant with the age between 0 and 36 months.
3. Use according to claim 1 or 2, wherein the composition further comprises at least one component selected from the group consisting of fructo-oligosaccharide, galacto-oligosaccharides (including transgalacto-oligosaccharides), casein, lactose, hydrolyzed whey protein and hydrolyzed casein.
4. Use according to any one of the preceding claims wherein the composition comprises docosahexaenoic acid (DHA).
5. Use according to any one of the preceding claims, wherein the composition is a liquid comprising between 0.3 and 0.55 g LA per 100 ml and between 50 and 150 mg ALA per 100 ml.
6. Use according to any one of the preceding claims, wherein at least 90 wt.% of the digestible carbohydrate is lactose.
7. Use according to any one of the preceding claims for preventing the development of a disorder selected from the group consisting of diabetes, visceral adiposity and/or cardiovascular diseases.
8. Use according to any one of the preceding claims, wherein the nutritional composition is administered to a human with the age below 18 months.
9. Use according to any one of the preceding claims, wherein arachidonic acid content does not exceed 0.5 wt.% based on total fatty acids.
10. Use according to any one of the preceding claims, wherein the composition comprises hydrolyzed casein and/or hydrolyzed whey protein.
11. Use of a composition comprising a galactooligosaccharides and/or long chain polyunsaturated fatty acid for the manufacture of a nutritional composition to be administered to a non-obese human with the age below 36 months and for preventing the development of a disorder when said human has an age above 36 months, wherein said disorder is selected from the group consisting of type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea.
PCT/NL2006/050274 2005-12-22 2006-11-02 Use of nutritional compositions for preventing disorders WO2008054192A1 (en)

Priority Applications (69)

Application Number Priority Date Filing Date Title
PCT/NL2006/050274 WO2008054192A1 (en) 2006-11-02 2006-11-02 Use of nutritional compositions for preventing disorders
RU2008130370/13A RU2417712C2 (en) 2005-12-23 2006-12-22 Nutritional composition intended for prevention of baby adiposity
HUE06824326A HUE026440T2 (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
US12/158,857 US20110136732A1 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
BRPI0620465-1A BRPI0620465A2 (en) 2005-12-23 2006-12-22 use of a composition
MYPI20082246A MY149164A (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
CA002634693A CA2634693A1 (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
MYPI20082247A MY172306A (en) 2005-12-23 2006-12-22 Use of nutritional compositions with phospholipid, sphingolipid and cholesterol
CA002634117A CA2634117A1 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
CN2006800533029A CN101384184B (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
NZ569264A NZ569264A (en) 2006-11-02 2006-12-22 Infant nutritional compositions for preventing obesity comprising linoleic acid
CA002634895A CA2634895A1 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
AU2006327997A AU2006327997B2 (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
PL06824326T PL1962823T3 (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
PCT/NL2006/050331 WO2007073194A2 (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
CN2006800513063A CN101389227B (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
CN201310014398.XA CN103054048B (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
BRPI0620466-0A BRPI0620466A2 (en) 2005-12-22 2006-12-22 use of a composition
EP06824326.0A EP1962823B1 (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
ES06824326.0T ES2537080T3 (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and / or molybdenum to improve the composition of cell membranes
AU2006327996A AU2006327996B2 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
PT68243260T PT1962823E (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
CN200680051657.4A CN101360489B (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
JP2008547136A JP2009521214A (en) 2005-12-23 2006-12-22 Infant nutrition composition for obesity prevention
EP11150747A EP2305049A1 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
EP06824324.5A EP1973424B1 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
AU2006327995A AU2006327995B2 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
PCT/NL2006/050329 WO2007073193A2 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
EP06824323A EP1962617A2 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
BRPI0620451-1A BRPI0620451A2 (en) 2005-12-23 2006-12-22 use of a composition comprising a digestible lipid, protein and carbohydrate component
RU2008130365/13A RU2444210C2 (en) 2005-12-23 2006-12-22 Baby nutritional compositions intended for prevention of adiposity
US12/158,931 US20090186803A1 (en) 2005-12-23 2006-12-22 Use of nutritional compositions with phospholipid, sphingolipid and cholesterol.
PCT/NL2006/050328 WO2007073192A2 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
RU2008130367/15A RU2414905C2 (en) 2005-12-23 2006-12-22 Application of nutrient compositions with phospholipids, sphingolipids and cholesterol
MYPI20082287A MY162091A (en) 2005-12-23 2006-12-23 Infant nutritional compositions for preventing obesity
ARP060105798A AR058751A1 (en) 2005-12-23 2006-12-26 FOOD COMPOSITIONS FOR BABIES TO PREVENT OBESITY
ARP060105800A AR058753A1 (en) 2005-12-23 2006-12-26 USE OF NUTRITIONAL COMPOSITIONS WITH SPHINGOLIPID PHOSPHOLIPIDS AND CHOLESTEROL
ARP060105799A AR058752A1 (en) 2005-12-23 2006-12-26 COMPOSITIONS FOR BABIES TO PREVENT OBESITY
US12/513,428 US20100068149A1 (en) 2006-11-02 2007-04-19 Use of nutritional compositions for preventing disorders
PCT/NL2007/050162 WO2008054200A2 (en) 2006-11-02 2007-04-19 Use of nutritional compositions for preventing disorders
RU2009120708/15A RU2446827C2 (en) 2006-11-02 2007-04-19 Use of food compositions for prevention of diseases
EP07747386.6A EP2077902B1 (en) 2006-11-02 2007-04-19 Use of nutritional compositions for preventing visceral adiposity
MYPI20091766A MY151018A (en) 2006-11-02 2007-04-19 Use of nutritional compositions for preventing disorders
ES07747386T ES2571856T3 (en) 2006-11-02 2007-04-19 Use of nutritional compositions to prevent visceral adiposity
AU2007314721A AU2007314721B2 (en) 2006-11-02 2007-04-19 Use of nutritional compositions for preventing disorders
MYPI2012001164A MY176679A (en) 2005-12-23 2007-04-19 Use of nutritional compositions for preventing disorders
EP16150456.8A EP3025643B1 (en) 2006-11-02 2007-04-19 Method to determine visceral adipose tissue in infants
CN201610573964.4A CN106172792A (en) 2006-11-02 2007-04-19 Alimentation composition is used for prophylactic purposes
EP17203951.3A EP3335710A3 (en) 2006-11-02 2007-04-19 Use of nutritional compositions for preventing disorders
CA2667856A CA2667856C (en) 2006-11-02 2007-04-19 Use of nutritional compositions for preventing disorders
PL07747386.6T PL2077902T3 (en) 2006-11-02 2007-04-19 Use of nutritional compositions for preventing visceral adiposity
CN200780048216.3A CN101568361B (en) 2006-11-02 2007-04-19 Alimentation composition is used for prophylactic purposes
ARP070104861A AR063773A1 (en) 2006-11-02 2007-10-31 USE OF NUTRITIONAL COMPOSITIONS TO PREVENT DISORDERS
ARP070104862A AR063774A1 (en) 2006-11-02 2007-10-31 USE OF NUTRITIONAL COMPOSITIONS TO PREVENT DISORDERS
EP12175365.1A EP2510811A3 (en) 2006-11-02 2007-11-01 Use of nutritional compositions for preventing disorders
JP2009535225A JP2010509210A (en) 2006-11-02 2007-11-01 Use of nutritional compositions to prevent injury
US12/513,472 US20100075900A1 (en) 2006-11-02 2007-11-01 Use of Nutritional Compositions for Preventing Disorders
AU2007314729A AU2007314729B2 (en) 2006-11-02 2007-11-01 Use of nutritional compositions for preventing disorders
CN2007800446186A CN101573048B (en) 2006-11-02 2007-11-01 Use of nutritional compositions for preventing disorders
BRPI0717969-3A BRPI0717969A2 (en) 2006-11-02 2007-11-01 USE OF A COMPOSITION.
EP12175396.6A EP2508178A3 (en) 2006-11-02 2007-11-01 Use of nutritional compositions for preventing disorders
EP07834655.8A EP2077728B1 (en) 2006-11-02 2007-11-01 Use of nutritional compositions for preventing disorders
NZ576665A NZ576665A (en) 2006-11-02 2007-11-01 Use of a nutritional composition for the prevention of visceral fat accumulation in infants
RU2009120668/13A RU2444912C2 (en) 2006-11-02 2007-11-01 Application of nutritive compositions for diseases prevention
PCT/NL2007/050525 WO2008054208A2 (en) 2006-11-02 2007-11-01 Use of nutritional compositions for preventing disorders
CA002667759A CA2667759A1 (en) 2006-11-02 2007-11-01 Use of nutritional compositions for preventing disorders
US13/357,109 US8871218B2 (en) 2005-12-23 2012-01-24 Infant nutritional compositions for preventing obesity
US14/553,166 US20150094257A1 (en) 2006-11-02 2014-11-25 Use of nutritional compositions for preventing disorders
US15/057,324 US20160175393A1 (en) 2005-12-23 2016-03-01 Use of nutritional compositions with phospholipid sphingolipid and cholesterol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2006/050274 WO2008054192A1 (en) 2006-11-02 2006-11-02 Use of nutritional compositions for preventing disorders

Publications (1)

Publication Number Publication Date
WO2008054192A1 true WO2008054192A1 (en) 2008-05-08

Family

ID=38222322

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/NL2006/050274 WO2008054192A1 (en) 2005-12-22 2006-11-02 Use of nutritional compositions for preventing disorders
PCT/NL2007/050162 WO2008054200A2 (en) 2006-11-02 2007-04-19 Use of nutritional compositions for preventing disorders
PCT/NL2007/050525 WO2008054208A2 (en) 2006-11-02 2007-11-01 Use of nutritional compositions for preventing disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/NL2007/050162 WO2008054200A2 (en) 2006-11-02 2007-04-19 Use of nutritional compositions for preventing disorders
PCT/NL2007/050525 WO2008054208A2 (en) 2006-11-02 2007-11-01 Use of nutritional compositions for preventing disorders

Country Status (14)

Country Link
US (3) US20100068149A1 (en)
EP (6) EP3025643B1 (en)
JP (1) JP2010509210A (en)
CN (3) CN101568361B (en)
AR (2) AR063774A1 (en)
AU (2) AU2007314721B2 (en)
BR (1) BRPI0717969A2 (en)
CA (2) CA2667856C (en)
ES (1) ES2571856T3 (en)
MY (1) MY151018A (en)
NZ (2) NZ569264A (en)
PL (1) PL2077902T3 (en)
RU (2) RU2446827C2 (en)
WO (3) WO2008054192A1 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054200A3 (en) * 2006-11-02 2009-05-07 Nutricia Nv Use of nutritional compositions for preventing disorders
WO2010112429A1 (en) 2009-04-01 2010-10-07 Nestec S.A. Reduction of risk of obesity
WO2010134800A1 (en) * 2009-05-19 2010-11-25 N.V. Nutricia Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution
WO2011071365A1 (en) * 2009-12-07 2011-06-16 N.V. Nutricia Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding
WO2010119088A3 (en) * 2009-04-15 2011-06-30 Bodo Melnik Milk and milk-based products modified to exhibit a reduced insulinemic index and/or reduced mitogenic activity
WO2012009426A1 (en) * 2010-07-13 2012-01-19 Abbott Laboratories High tolerance infant formula including hydrolyzed protein
EP2452574A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
EP2452571A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Array of complementary infant/young child nutritional compositions
EP2452572A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for infants and children
EP2452573A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
WO2012177135A1 (en) 2011-06-22 2012-12-27 N.V. Nutricia Method for reducing the occurrence of infection in young children
WO2013036122A1 (en) 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with large lipid globules
WO2013036119A1 (en) 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with cholesterol
US8586077B2 (en) 2009-01-19 2013-11-19 Nestec S.A. Nutritional composition for infants
EP2759296A1 (en) * 2011-09-15 2014-07-30 Kao Corporation Gip elevation inhibitor
WO2014150566A1 (en) * 2013-03-15 2014-09-25 Mjn U.S. Holdings Llc Reducing the risk of autoimmune disease
WO2015078974A1 (en) * 2013-11-29 2015-06-04 Nestec S.A. Infant nutrition for improvement in insulin sensitivity later in life
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
EP2774615A4 (en) * 2011-10-17 2016-02-17 Kao Corp Agent for increasing amount of muscles
US9320294B2 (en) 2008-09-02 2016-04-26 N.V. Nutricia Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US9457058B2 (en) 2013-03-15 2016-10-04 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with anti-inflammatory properties and uses thereof
US9474764B2 (en) 2010-03-17 2016-10-25 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes
WO2017064309A1 (en) * 2015-10-15 2017-04-20 N.V. Nutricia Infant formula with milk fat for promoting healthy growth
US9668942B2 (en) 2012-02-17 2017-06-06 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
WO2018149907A1 (en) * 2017-02-20 2018-08-23 Nestec S.A. Nutritional compositions with partially hydrolysed proteins for use in inducing glucose and/or insulin response(s) close to the ones observed with human milk
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula
US11376222B2 (en) 2013-11-01 2022-07-05 N.V. Nutricia Lipid composition for improving body composition during catch-up growth
US11389403B2 (en) 2015-10-15 2022-07-19 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
US11632974B2 (en) 2016-12-09 2023-04-25 N.V. Nutricia Nutritional composition for improving cell membranes

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541472B2 (en) * 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
JP5238373B2 (en) * 2008-06-25 2013-07-17 株式会社ヤクルト本社 Mesenteric fat reducing agent
WO2010106384A1 (en) * 2009-03-16 2010-09-23 Societe La Biochimie Appliquee (Solabia) Glucooligosaccharide nutraceutical, pharmaceutical, or food compositions
BRPI1014065A2 (en) 2009-04-03 2016-04-12 Nestec Sa improves the promotion of healthy compensatory growth
ES2555032T3 (en) 2010-01-19 2015-12-28 Mjn U.S. Holdings Llc Nutritional compensation for western type diet
US20110208153A1 (en) * 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
WO2011119023A1 (en) 2010-03-26 2011-09-29 N.V. Nutricia Low protein infant formula with increased essential amino acids
EP2502507A1 (en) * 2011-03-21 2012-09-26 Abbott Laboratories Methods for improving bone health in infants using prebiotics
WO2012173467A1 (en) 2011-06-16 2012-12-20 N.V. Nutricia Metabolic imprinting effects of specifically designed lipid component
SE536599C3 (en) 2012-04-10 2017-01-10 Hero Ag Nutritional composition with low calorie and low protein content
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
US20140328970A1 (en) * 2013-05-03 2014-11-06 Mead Johnson Nutrition Company Nutritional Composition Comprising Whey and Hydrolyzed Casein and Uses Thereof
US20160124002A1 (en) * 2013-06-14 2016-05-05 Seoul National University R&Db Foundation Method for detecting hypoxia or diagnosing hypoxia-related diseases
KR101446873B1 (en) 2013-06-14 2014-10-06 서울대학교산학협력단 Biomarkers for diagnosing sleep apnea and its uses
WO2015013678A2 (en) * 2013-07-25 2015-01-29 Iycus, Llc Stable fatty acid compositions
CN104413147A (en) * 2013-09-11 2015-03-18 中粮营养健康研究院有限公司 Grease composition for formula milk powder as well as preparation method and application of grease composition
US11252986B2 (en) 2013-11-29 2022-02-22 Societe Des Produits Nestle S.A. Use of nutritional compositions having a low protein amount
EP3200619A1 (en) * 2014-09-30 2017-08-09 Nestec S.A. Nutritional composition with low content of medium-chain fatty acids in specific proportions, and its uses.
US10987368B2 (en) * 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US20180067129A1 (en) * 2015-03-17 2018-03-08 Duke University Compositions and Methods for Identifying and Modulating Metabolic Health
JP6613661B2 (en) * 2015-07-08 2019-12-04 花王株式会社 Evaluation method of difficulty in attaching visceral fat to food
EP3407740A1 (en) * 2016-01-26 2018-12-05 Nestec S.A. COMPOSITIONS COMPRISING 2FL AND LNnT TO CONTROL FOOD INTAKE AND GROWTH IN INFANTS OR YOUNG CHILDREN
AU2017251143B2 (en) 2016-04-11 2021-05-20 Société des Produits Nestlé S.A. Infant nutrition delivering metabolic benefits
PT3454674T (en) * 2016-05-10 2021-03-09 Nutricia Nv Fermented infant formula
WO2019092021A1 (en) * 2017-11-09 2019-05-16 Nestec S.A. An array of age-tailored nutritional formula for infants and young children for use in the prevention of sub-optimal body composition
WO2019168149A1 (en) 2018-03-02 2019-09-06 一般財団法人糧食研究会 Peptide capable of improving cognitive function
EP3821813B1 (en) * 2018-07-13 2024-07-31 Furuno Electric Co., Ltd. Ultrasound imaging device, ultrasound imaging system, ultrasound imaging method and ultrasound imaging program
WO2020161113A1 (en) * 2019-02-04 2020-08-13 N.V. Nutricia Fermented formula with non digestible oligosaccharides for sleep improvement
KR20230011679A (en) * 2021-07-14 2023-01-25 최명석 Dietary composition on the regulation and prevention of obesity
RU2761164C1 (en) * 2021-07-16 2021-12-06 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр питания, биотехнологии и безопасности пищи Method for treatment of patients with non-alcoholic fatty liver disease using specialized food product
RU2761163C1 (en) * 2021-07-16 2021-12-06 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр питания, биотехнологии и безопасности пищи Specialized food product intended for nutrition of patients during the period of treatment of non-alcoholic fat liver disease
CN115736261A (en) * 2022-12-07 2023-03-07 中国科学院深圳先进技术研究院 Ketogenic dietary composition and preparation method and application thereof
WO2024200714A1 (en) * 2023-03-29 2024-10-03 Frieslandcampina Nederland B.V. Low calory infant nutrition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006009437A2 (en) * 2004-07-19 2006-01-26 N.V. Nutricia Use of aspartate for regulating glucose levels in blood
WO2006057551A1 (en) * 2004-11-26 2006-06-01 N.V. Nutricia Infant nutrition with protease inhibitor
WO2006091103A2 (en) * 2005-02-28 2006-08-31 N.V. Nutricia Nutritional composition with probiotics
WO2007073192A2 (en) * 2005-12-23 2007-06-28 N.V. Nutricia Infant nutritional compositions for preventing obesity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1062873A1 (en) * 1999-12-13 2000-12-27 N.V. Nutricia Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate
US6495599B2 (en) * 2000-04-13 2002-12-17 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses therof
WO2003005836A2 (en) 2001-07-10 2003-01-23 Trustees Of Boston University Modified-fat nutritional products useful for preventing or treating obesity
IL158554A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Mimetic lipids as dietary supplements
JP4943853B2 (en) 2003-10-24 2012-05-30 エヌ．ブイ．・ヌートリシア Immunomodulatory oligosaccharides
WO2005063050A1 (en) 2003-12-19 2005-07-14 Abbott Laboratories Method of increasing lean body mass and reducing body fat mass in infants
US7413295B2 (en) * 2004-03-19 2008-08-19 Brother Kogyo Kabushiki Kaisha Inkjet printer with delivery chamber
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
DE602005026456D1 (en) * 2004-12-27 2011-03-31 Nestec Sa USE OF INFANT FOOD WITH REDUCED PROTEIN CONTENT
FI20055090A (en) * 2005-02-24 2006-08-25 Elcoteq Se locking Means
US20090203592A1 (en) 2005-07-01 2009-08-13 N.V. Nutricia Infant nutrition with hydrolised proteins
WO2008054192A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
WO2007118073A2 (en) * 2006-04-03 2007-10-18 Joslin Diabetes Center, Inc. Obesity and body fat distribution

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006009437A2 (en) * 2004-07-19 2006-01-26 N.V. Nutricia Use of aspartate for regulating glucose levels in blood
WO2006057551A1 (en) * 2004-11-26 2006-06-01 N.V. Nutricia Infant nutrition with protease inhibitor
WO2006091103A2 (en) * 2005-02-28 2006-08-31 N.V. Nutricia Nutritional composition with probiotics
WO2007073192A2 (en) * 2005-12-23 2007-06-28 N.V. Nutricia Infant nutritional compositions for preventing obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AILHAUD ET AL: "Temporal changes in dietary fats: Role of n-6 polyunsaturated fatty acids in excessive adipose tissue development and relationship to obesity", PROGRESS IN LIPID RESEARCH, PERGAMON PRESS, PARIS, FR, vol. 45, no. 3, May 2006 (2006-05-01), pages 203 - 236, XP005399131, ISSN: 0163-7827 *

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054200A3 (en) * 2006-11-02 2009-05-07 Nutricia Nv Use of nutritional compositions for preventing disorders
US9345259B2 (en) 2008-09-02 2016-05-24 N.V. Nutricia Nutritional compositions with coated lipid globules
US9320294B2 (en) 2008-09-02 2016-04-26 N.V. Nutricia Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids
US9700568B2 (en) 2008-09-02 2017-07-11 N.V. Nutricia Nutritional compositions with coated lipid globules
US9707240B2 (en) 2008-09-02 2017-07-18 N.V. Nutricia Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids
US8999926B2 (en) 2009-01-19 2015-04-07 Nestec S.A. Nutritional composition for infants
US8586077B2 (en) 2009-01-19 2013-11-19 Nestec S.A. Nutritional composition for infants
WO2010112429A1 (en) 2009-04-01 2010-10-07 Nestec S.A. Reduction of risk of obesity
US9480671B2 (en) 2009-04-01 2016-11-01 Nestec S.A. Reduction of risk of obesity
US9480670B2 (en) 2009-04-01 2016-11-01 Nestec S.A. Reduction of risk of obesity
WO2010119088A3 (en) * 2009-04-15 2011-06-30 Bodo Melnik Milk and milk-based products modified to exhibit a reduced insulinemic index and/or reduced mitogenic activity
EP2432333B1 (en) 2009-05-19 2020-10-14 N.V. Nutricia Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution
WO2010134800A1 (en) * 2009-05-19 2010-11-25 N.V. Nutricia Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution
WO2010134810A1 (en) * 2009-05-19 2010-11-25 N.V. Nutricia Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution
US9089533B2 (en) 2009-05-19 2015-07-28 N. V. Nutricia Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution
CN102753027A (en) * 2009-12-07 2012-10-24 N·V·努特里奇亚 Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding
WO2011071365A1 (en) * 2009-12-07 2011-06-16 N.V. Nutricia Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding
WO2011071376A1 (en) * 2009-12-07 2011-06-16 N.V. Nutricia Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding
US9044043B2 (en) 2009-12-07 2015-06-02 N.V. Nutricia Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding
RU2546865C2 (en) * 2009-12-07 2015-04-10 Н.В. Нютрисиа Balanced fat compositions and their application in liquid nutritional compositions for enteral feeding
CN102753027B (en) * 2009-12-07 2014-12-17 N·V·努特里奇亚 Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding
US10548869B2 (en) 2010-03-17 2020-02-04 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes
US9474764B2 (en) 2010-03-17 2016-10-25 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes
WO2012009426A1 (en) * 2010-07-13 2012-01-19 Abbott Laboratories High tolerance infant formula including hydrolyzed protein
EP2452573A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
WO2012065813A1 (en) * 2010-11-15 2012-05-24 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
WO2012065812A1 (en) * 2010-11-15 2012-05-24 Nestec S.A. Array of complementary infant/young child nutritional compositions
EP2452572A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for infants and children
EP2452571A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Array of complementary infant/young child nutritional compositions
EP2640199A1 (en) * 2010-11-15 2013-09-25 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
EP2452574A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
CN103209604A (en) * 2010-11-15 2013-07-17 雀巢产品技术援助有限公司 Age-tailored nutritional formula with particularly adapted caloric density for infants and children
RU2586915C2 (en) * 2010-11-15 2016-06-10 Нестек С.А. Age-tailored nutritional formula with adapted caloric value for infants and children
WO2012065809A1 (en) * 2010-11-15 2012-05-24 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for infants and children
WO2012065810A1 (en) * 2010-11-15 2012-05-24 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
WO2012177118A1 (en) * 2011-06-22 2012-12-27 N.V. Nutricia Method for reducing the occurrence of infection in young children
WO2012177135A1 (en) 2011-06-22 2012-12-27 N.V. Nutricia Method for reducing the occurrence of infection in young children
RU2605198C2 (en) * 2011-06-22 2016-12-20 Н.В. Нютрисиа Method for reducing the occurence of infection in infants
CN103732080A (en) * 2011-06-22 2014-04-16 N·V·努特里奇亚 Method for reducing the occurrence of infection in young children
EP3469921A1 (en) * 2011-06-22 2019-04-17 N.V. Nutricia Method for reducing the occurrence of infection in young children
US9427445B2 (en) 2011-06-22 2016-08-30 N.V. Nutricia Method for reducing the occurrence of infection in young children
WO2013036122A1 (en) 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with large lipid globules
EP2753191B1 (en) 2011-09-08 2017-07-12 N.V. Nutricia Use of infant formula with large lipid globules
EP2753190B1 (en) 2011-09-08 2017-05-03 N.V. Nutricia Use of infant formula with cholesterol
WO2013036119A1 (en) 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with cholesterol
EP2759296A1 (en) * 2011-09-15 2014-07-30 Kao Corporation Gip elevation inhibitor
US10045957B2 (en) 2011-09-15 2018-08-14 Kao Corporation GIP elevation inhibitor
EP2759296A4 (en) * 2011-09-15 2015-04-29 Kao Corp Gip elevation inhibitor
EP2774615A4 (en) * 2011-10-17 2016-02-17 Kao Corp Agent for increasing amount of muscles
US9668942B2 (en) 2012-02-17 2017-06-06 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
US10987280B2 (en) 2012-02-17 2021-04-27 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
US10828239B2 (en) 2012-02-17 2020-11-10 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
US9687420B2 (en) 2012-02-17 2017-06-27 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
US12059391B2 (en) 2012-02-17 2024-08-13 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
US11998511B2 (en) 2012-02-17 2024-06-04 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
US10632047B2 (en) 2012-02-17 2020-04-28 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
US9775784B2 (en) 2012-02-17 2017-10-03 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
US9775783B2 (en) 2012-02-17 2017-10-03 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
US11872191B2 (en) 2012-02-17 2024-01-16 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
WO2014150566A1 (en) * 2013-03-15 2014-09-25 Mjn U.S. Holdings Llc Reducing the risk of autoimmune disease
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9457058B2 (en) 2013-03-15 2016-10-04 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with anti-inflammatory properties and uses thereof
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US11376222B2 (en) 2013-11-01 2022-07-05 N.V. Nutricia Lipid composition for improving body composition during catch-up growth
WO2015078974A1 (en) * 2013-11-29 2015-06-04 Nestec S.A. Infant nutrition for improvement in insulin sensitivity later in life
US10821150B2 (en) 2013-11-29 2020-11-03 Societe Des Produits Nestle S.A. Infant nutrition for improvement in insulin sensitivity later in life
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
US11045440B2 (en) 2015-10-14 2021-06-29 Alcresta Therapeutics, Inc. Enteral feeding devices and related methods of use
US11944596B2 (en) 2015-10-14 2024-04-02 Alcresta Therapeutics, Inc. Enteral feeding devices and related methods of use
US11389403B2 (en) 2015-10-15 2022-07-19 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
RU2728720C2 (en) * 2015-10-15 2020-07-30 Н.В. Нютрисиа Infant formula with milk fat for healthy growth stimulation
WO2017064309A1 (en) * 2015-10-15 2017-04-20 N.V. Nutricia Infant formula with milk fat for promoting healthy growth
US11632974B2 (en) 2016-12-09 2023-04-25 N.V. Nutricia Nutritional composition for improving cell membranes
WO2018149907A1 (en) * 2017-02-20 2018-08-23 Nestec S.A. Nutritional compositions with partially hydrolysed proteins for use in inducing glucose and/or insulin response(s) close to the ones observed with human milk
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula

Also Published As

Publication number Publication date
US20100075900A1 (en) 2010-03-25
EP3335710A3 (en) 2018-09-12
CN101568361B (en) 2016-08-17
CN101568361A (en) 2009-10-28
CA2667856C (en) 2015-11-24
PL2077902T3 (en) 2016-09-30
BRPI0717969A2 (en) 2013-11-12
EP2077902A2 (en) 2009-07-15
WO2008054208A3 (en) 2008-10-16
AR063773A1 (en) 2009-02-18
EP2510811A2 (en) 2012-10-17
EP2077902B1 (en) 2016-03-23
EP3335710A2 (en) 2018-06-20
CA2667759A1 (en) 2008-05-08
EP3025643A1 (en) 2016-06-01
MY151018A (en) 2014-03-31
NZ576665A (en) 2012-01-12
CN106172792A (en) 2016-12-07
CN101573048A (en) 2009-11-04
WO2008054200A3 (en) 2009-05-07
RU2009120708A (en) 2010-12-10
WO2008054208A2 (en) 2008-05-08
RU2446827C2 (en) 2012-04-10
WO2008054200A2 (en) 2008-05-08
EP2508178A2 (en) 2012-10-10
EP3025643B1 (en) 2017-11-29
AU2007314721A1 (en) 2008-05-08
US20100068149A1 (en) 2010-03-18
EP2077728B1 (en) 2016-12-21
NZ569264A (en) 2011-09-30
AU2007314729B2 (en) 2013-04-18
EP2510811A3 (en) 2018-01-03
AU2007314721B2 (en) 2013-09-05
RU2444912C2 (en) 2012-03-20
JP2010509210A (en) 2010-03-25
ES2571856T3 (en) 2016-05-27
CA2667856A1 (en) 2008-05-08
EP2508178A3 (en) 2018-01-03
AU2007314729A1 (en) 2008-05-08
US20150094257A1 (en) 2015-04-02
RU2009120668A (en) 2010-12-10
CN101573048B (en) 2013-12-25
EP2077728A2 (en) 2009-07-15
AR063774A1 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
AU2007314729B2 (en) Use of nutritional compositions for preventing disorders
EP1973424B1 (en) Infant nutritional compositions for preventing obesity
USRE45483E1 (en) Infant nutritional compositions for preventing obesity
EP2720563A1 (en) Metabolic imprinting effects of specifically designed lipid component
WO2010027258A1 (en) Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids
US20120322756A1 (en) Metabolic imprinting effects of structured lipids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06812733

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06812733

Country of ref document: EP

Kind code of ref document: A1